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INTRODUCTION 
Siddha system of Medicine is an antidiluvian  system of medicine which is 
developed and enriched by paramount powers called Siddhars .Siddha system of 
Medicine is nothing but a part of tamil civilization which is the only civilization alive 
Pre-Historical Periods. 
As per traditional Fiction, it is considered that lord Shiva uncoiled his 
Knowledge about Siddha to his divine concomitant  goddess parvathi. She then 
revealed it to nandidev ,who inturn handed it to primordial guru AGASTHIYAR ,who 
in turn   handed it to his disciples. 
The Word “Siddha” is derived from the root word “Siddhi” Which means an 
object to be Obtained (or) Attained .  Siddhi mainly deals with Ashtama Siddhi ie.., 8 
Supernatural powers. The persons who gained the above said powers are called as 
Siddhars. 
Siddhars  are considered as the great experts. They are highly cultured 
,intellectual   &  Spiritual  along  with  the  Supernatural  Powers.Siddhars   are  well-
versed in handling  4 different divisions  which are related & inter-mingled with each 
other(1. Vadham;  2.Vaidyam; 3.Gnanam & 4.Yogam). 
The art of Longevity and the attempts of immortalising the corporeal human 
body were Considered as the ultimate Goal of Siddhars.  This goal is achieved by 
deep & severe yogic  practices; including  years of periodic  fasting& medication and 
gains Supernatural powers, supreme wisdom and overall immortality. 
Siddhars  have an enormous amount of knowledge regarding chemicals, 
metals, minerals and plants  which were successfully used by them for curing various 
disease. 
The special features  in Siddha system of medicine are Calcination of 
Mercury, Minerals, Metals & the preparation of a Supreme Salt Known as Muppu [a 
crown of Siddha]  and rejunvenating the entire human system. 
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In Siddha system, Chemistry had been found developed into a science 
auxillary  to MEDICINE(Vaidhiyam) and ALCHEMY(Vadham). It was found usefull 
in  the  preparation  of  medicine  for  curing  all  sorts  of  sufferings,  Spiritual  as  well  as  
corporeal & also in transmutation of baser Metals into Gold. 
The siddhars school fully recognises that there are 96 tatwas and further 
believes that the human body is composed of 72000 naadi, 30000 nerves, 10 main 
artries  ,10  vital  airs  (prana)  all  together  in  the  form   of  a  network.  The  normal  
functioning of human body depends on homeostasis of three forces or three humors 
called vadham,pitham,kabam. Any derangement in this homeostasis leads to 
pathological condition called Pini or Noi ,which is classified into 4448 in number. 
This well explain in the following verses from “Ishwara’s Meignana Naadi” 
According to yugi vaithya  chinthamani 800 vadha disease is of 80 types. 
uthira vadha suronitham is one among them. Day by day prevalence of vadha diseases 
increases due to environmental changes and life style modification of the human 
beings  .   Among  arthritis  ,  Rheumatoid  arthritis  scores  more  clinical  importance  
because of its crippling nature. It affects not only the patients even their  friends and 
neighbours  physically, mentally and emotionally . 
The symptoms of uthiravadhasuronitham is similar to that of Rheumatoid 
arthritis  in  morden  aspect.  Rheumatoid  arthritis  is  an  auto  immune  disease.  It  is  
common chronic  inflammatory, destructive and deforming symmetrical polyarthritis 
associated with systemic involvement.The individuals with HLA D4 and HLA DR4 
are more prone to RA. About 0.5% to 1% world population are prone to RA In India 
nearly 7million (0.75%) people are suffering from RA. 
In Rheumatoid arthritis, various analgesic drug (NSAID) have been used .In 
failure of NSAID drug in advanced cases immune suppressive (DMARDS) drugs 
were used.Frequent usage of analgesic  associated with adverse effect like gastric 
irritation, skin rashes, nausea , vomiting , epigastric pain, renal and hepatic 
dysfunction,blood dyscariasis,etc…. 
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So the author tries to evaluate a Siddha herbo mineral formulation 
GANDHAGA RASAYANAM (INT) mentioned in ATHMA RATCHAMIRTHAM 
and NAVANATHA SIDDHA THYLAM (EXT) mentioned THERAN 
THAILAVARGA SURUKKAM for the treatment of UTHIRA VADHA 
SURONITHAM(RA). 
  
  
 
 
                                                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  
                               AIM AND OBJECTIVES           
 
4 
 
AIM:
                                                                                                                                                                                      
The principle aim of the present study is to evaluate the therapeutic efficacy of 
the siddha formulation “GANDHAGA RASAYANAM” (INT) and  
NAVANATHASITTHA THAILAM” (EXT) in the treatment of  “ 
UTHIRAVATHA SURONITHAM” (Rhematoid arthritis). 
OBJECTIVE: 
 Primary objective: 
             To analysis the safety therapeutic efficacy of Siddha drug  GANDHAGA 
RASAYANAM” (INT) and  NAVANATHASITTHA THAILAM” (EXT) in the 
treatment of “ UTHIRAVATHA SURONITHAM” (Rheumatoid arthritis). 
 Secondary objective: 
             To carryout a clinical trial with a precise proforma on identified patient with “ 
UTHIRAVATHA SURONITHAM” (Rheumatoid arthritis). 
             To  review  the  extend  of  equation  of  etiology,  clinical  features,  signs  and  
symptoms  of   UTHIRAVATHA  SURONITHAM   in  siddha  aspect  with  RA  in  
morden medicine. 
             To analyse the disease uthiravatha suronitham according to the rational of 
udal thathu, paruva kalam, enn vagai thervu, neerkuri and nei kuri, age, sex, diet, 
family history, socio-economic condition. 
             To interpret altered tridosa or mukkutram and changes in the physiology as 
per siddha aspect. 
              To carryout comprehensive analysis to manifest the clinical efficacy of the 
drugs through the pharmacological and biochemical analysis. 
              To conduct clinical analysis on uthiravatha suronitham in both 20 inpatient 
and 20 outpatient department. 
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              To diagnose the disease on the basis of modern parameters  and Siddha 
diagnostic parameter. 
               To carryout bio-stastistical analysis of trial drug. 
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SIDDHA ASPECT 
VATHAM: 
Vatham governs all movement in the mind and body. It controls 
blood flow, elimination of waste, breathing and movement of thoughts 
across the mind. 
Vatham derives from elements of space and air. Vatham is  nothing 
but the energy of movement and the drive governing all biological 
activity. Vatha  dosham is considered as the “king of the doshas”, since it 
maintains the body’s greater life force and helps in the movement of 
pittam and kabam. 
              This is well explained in following verses: 
                              “nghw;whkiuahd; Gidnka; auz;fhf;Fk; 
              nghw;whkiuahd; Gfy;tnjd; nghw;whk; 
              tstpdpNyahf;Fuk;igkd;dnddkd;d 
              tstpdpNyahf;Fk; tsp”. 
- Njud; akfntz;gh 
 
Vatham  is  considered  as  the  king  who  rules  the  body  [  fort]  and  
enables the wellbeing of the citizens [ uyir]. 
The balanced vatham is active, creative and gifted with a natural 
ability to direct and enlighten. 
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SITES OF VATHAM: 
According to vaidyachatakam, the sites of vatham are – umbilicus, 
rectum, faecal matter, abdomen, anus, bones, hip joints, navel, hair 
follicle, muscles and plexus. 
                                “mwpe;jpLk; thjklq;Fkyj;jpdpy;” 
-            -jpU%yH 
                                 “ehnkd;wthjj;Jf; fpUg;gplNkNfsha; 
                 ehgpf;Ff; fPnod;WetpyyhFk;” 
-             - A+fp 
           According to tirumoolar and yugi muni, the sites of vatham are the 
anus and the sub naval region. 
TYPES AND FUNCTIONS OF VATHAM : 
                   According to siddha classical texts the vatham is classified 
into 10 forms based on their location and function. They are: 
x Praanan  - life force / life air. 
x Abaanan – regulates defaecation, micturition, ejaculation, etc 
x Viyaanan – circulates the energy throughout the entire nervous 
system. 
x Udhaanan – responsible for physiological reflex actions like 
vomiting, hiccup, cough, etc 
x Samaanan – balances the other types of vatham 
x Naagan – responsible for intelligence of an individual, 
winking, singing, and pilo-erection. 
x Koorman – responsible for yawning, closing of mouth, 
winking, shedding of tears, vision and opening of eyes. 
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x Kirukaran-  helps in digestion and medication. Produces cough 
and sneeze. 
x Dhevathaathan – responsible for laziness , quarrelling , arguing 
x Dhananjeyan – intracranial air. 
INCASE OF UTHIRAVATHASURONITHAM : 
x Abaanan - causes constipation 
x Viyaanan – produces restricted joint movements 
x Samaanan – due to de-arrangement of other vathas 
x Kirukaran – produces loss of appetite 
x Dhevathathan – insomnia. 
Neha; jUk; top - AETIOLOGY :   
 I. According to YugiVaithyaSinthamani, 
 “vd;dNtthje;jhndz;gjhFk; 
  kpFj;jpNykdpjHfSf; nfa;JkhW 
 gpd;dNtnghe;jidNaNrhuQ; nra;J 
  nghpNahHfs; gpuhkziuj; J}\; zpj;Jk; 
 td;dNttr;nrhj;jpw; NrhuQ; nra;J 
  khjhgpjhFUitkwe;JNgHf;Fk; 
 fd;dNtNtjj;ijepe;ijnra;jNgHf;Fq; 
  fhaj;jpw; fye;jpLNkthje; jhNd”. 
  
 “jhndd;wfrg;NghLJtHg;Giug;G 
  rhjfkha; kpQ;RfpDQ; rikj;jtd;dk; 
 Mndd;wthwpdJnghrpj;jyhYk; 
  Mfhj; NjwyJFbj;jyhYk; 
 ghndd;wgfYwf;fkpuhtpopg;G 
  gl;bdpNakpfTWjy; ghunka;jy; 
 Njndd;wnkhopahw; Nkw; rpe;ijahfpy; 
  rPf;fpukha; thjkJnrdpf;Fe; jhNd”. 
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 “Mzhdtud;wndsNakjpahkhe;jH 
  mfjpguNjrpaHfl; fd;dkPahH 
 NfhdhdFunkhopiakwe;jNgHfs; 
  nfhiyfsTngha;fhkq; Fwpj;jNgHf;F 
 Cdhdrle;jd;dpy; thjk; te;J 
  cw;gtpf;Fk; Ntjj;jpYz;ikjhNd”. 
     A+fp itj;jparpe;jhkzp 
 
According to yugivaithiyachintamani, who are spending money in 
a reckless and foolish manner, neglecting or deserted the parents, cursing 
the holybooks, disrespecting the divine gifts, persons having deviltry 
mind and those with day slumber and staying back at night will get 
vatham disease. 
 
ACCORDING TO PARARASASEKARAM: 
 
njhopy; nghWifg;Gf;fhHj; jy;JtHj;jy; tpQ;RfpDQ;NrhWk; 
gioajhk; tuFkw;iwg; ige;jpidaUe;jpdhYk; 
vopy;ngwg; gfYwq;fp ,utpdpYwq;fhjhYk; 
kioepfHFoypdhNsthjq;Nfhgpf;Fq; fhNz. 
fhzNtkpfTz; lhYq; fUJgl; bdptpl; lh 
khdidahHfz; Nkhfkwf;fpDkpFe;jpl;lhYk; 
Mztkyq;flk;ikaq;qNdtplhjjhYk; 
thDjd; kley; yhNsthjq;Nfhgpf;Fq; fhNz. 
ghhpdpw; gag;gl;lhYk; gyUld; Nfhgpj; jhYk; 
fhnudf; fUfpNahbf; fOkuj; Juj;jpzhYk; 
VHngWjdJneQ;rpd; kpfj;Jf;fkile;jpl;lhYk; 
ghhpafhw;wpdhSk; glhpDk; thjq; fhZk;. 
fhyq;fz; khwpAz;Zq; fhhpaj; jhYe; jz;zPH 
rhyNtaUe;jpzYQ; re;jpapYl;fhHe; jhYk; 
Nfhykhk; Gspg;Gnea;ikf; FiwtwtUe;jpdhYk; 
thythHKiyey; yhNsthjKw; gtpf;Fq; fhNz. 
10 
 
cw;gtpj; njOkg; NghNjAaHGwj; Jbiag; gw;wpj; 
njw;gwf; File;JNehTQ; nra;JNkyNehf;Fkhfpy; 
tpw;nghypEjypdhNsNkypLq; Fzq;flk;kpy; 
nrhw;ngWthjk; Njhd;Wnkd; wwpe;Jnfhs;f 
        njhpe;JKd; nrhd;dtz;zQ; nra;afhybiag; gw;wp 
khe;jidg; Nghw;wpkpHj;Jkw;WNky; Nehf;Fkhfpy; 
        mud;widj; Jjpahkhe;juDrhpf; fpd;wNfhapy; 
rhpe;jpLq; Foyha; thjq; FbGFQ; rhw;Wq; fhNy.  
- ghuhrNrfuk; 
 
According to pararasasekaram, increased intake of grains, 
decreased intake of ghee and acrid acid, increased intake of food, 
increased fear, increased anger, increased sadness, increased exposure to 
forcible flow of air, altered dietary timings will produce vatham diseases. 
 
“fhdilahyr; rj;jhw; fLk;grpahw;Nfhgj;jhy; 
Cdkpyputpy; thHj;ijAuk;ngwtpiuf;fyhYhz; 
Mdgpd; Kdpthy; khUjLj;jLj; Jiuf;FQ; nrhy;yhy; 
<dkpypfo;r;rpahdtpfy;thjNfhgq; fhZk;.” 
- mq;fhjpghjk; 
       According to text angaathipatham, increased starvation and increased 
anger will produce disease of vatham. 
OTHER FACTORS THAT INFLUENCE VATHAM: 
1. DIETS : 
          “tspjUfha; fpoq;Ftiutpyhjapyy; Nfhio 
 GspjapHNghd; kpFf;FKiwapyhTz;bNfly; 
 FspHjUtspapw; Nwfq; Fdpg;GwTyty; ngz;bH 
 FspjUKaf;fk; ngw;NwhHfbnray; fUtpahky; 
- rghgjpifNaL 
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x Increased intake of tubers. 
x Increased intake of chill foods 
x Wandering in chill air 
x Getting drenched in rain 
x  Living in hilly region 
x  Excessive sexual indulgence 
x  Hereditary 
TASTES THAT MAY INCREASE THE VATHAKUTARM : 
“njhopy; ngWifg;Gf; fhHj;jy; JtHj;jy; tpQ;RfpDQ; NrhWk; 
  gioajhk; tuFkw;iwg; ige;jpidaUe;jpdhYk; 
  vopy; ngwg; gfYwq;fp ,utpdpYwq;fhjjhYk; 
  kioepfhFoypdhNythjq;Nfhgpf;Fq; fhNd” 
                   - A+fpitj;jparpe;jhkzp 
increased intake of bitter taste, astringents, sour taste, increased intake of old cooked 
rice, intake of grains, day slumber and staying back at night causes vatha diseases. 
2. HABITS : 
               “nta;apypy; eilf;ifahYk; kpfj;jz;zPHFbf;ifahYk; 
     nra;apiokfspdiur; NrHe;jDgtpf;ifahYk; 
     igaNdcz;ikahYk; ghfw;fha; jpd;ifahYk; 
     ijaNythjNuhfk; rdpf;Fnkd; wwpe;Jnfhs;Ns”. 
                -  NjiuaHthflk; 
According to theraiyarvaakadam, excessive walking in hot sun, excessive 
intake of water, bitterguard and increased sexual indulgence, may play a role in 
disturbing the normal functions of vatham. 
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3. ENVIRONMENTAL FACTORS : 
As per Siddha Maruthuvaanga Churukkam... 
      “gJkj;ijg; G+f;f itf;Fk; ghDkpff; fhAk; 
       KJNtdp ypw;G tpw;ePH Kw;Wk; - fJnkd 
       tw;Wk; fgkp‡Fk; thAkpFk; tho;khe;jf; 
      Fw;w eypf; Nfjpnjd; NwhJ” 
                 - rpj;j kUj;Jthq;f RUf;fk;  
According to siddha maruthuvaangachurukkam, in muthuvenilkaalam, the 
increased solar radiation increases the evaporation of water content from the body 
inturn produces increase in the kabam and vatham leading to formation of a disease. 
B. As per YUGIVAITHYASINTHAMANI… 
                             “thjtHj; jdfhyNkNjhntd;dpy; 
                      kUTfpd;wMdpfw;flkhjk; 
                      Mjidg; grpNahLfhHj;jpifjd;dpy; 
                     MlUNkkw;wkhjq;fs; jd;dpy; 
                     NghfNtrpkpf;fpd;wfhykhFk;” 
                 - A+fprpe;jhkzp 
As per yugivaithyasinthamani, the incidence of vatha diseases will be more in 
the months from aani to karthigai[ june – December]. 
UTHIRAVATHA SURONITHAM 
NOMENCLATURE: 
Uthiravathasuronitham=  uthiravatha + suronitham 
Uthiravatham = arthritis of rheumatic origin marked by severe pain and the 
formation of inflammatory nodules in the region of joints especially in the limbs of 
the body.(T.V.Sambasivam pillai). 
Suronitham = blood and menstrual blood. 
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DEFINITION : 
Uthiravathasuronitham is a type of arthritis of rheumatic origin. It is  
Characterized by pain, swelling, pricking sensation and restriction of movements due 
to de arranged vatham. 
1. According to YUGIVAITHIYASINTHAMANI: 
  itfpjkha;f; fizf;fhYKoq;fhy; jhDk; 
kw;flQ; re;JGwtbAk; tPq;fpr; 
nra;fpjkhw; rpWtpuy;fs; kpfTk; nehe;J 
rpe;ijjLkhwpNarypg;Gz;lhFk; 
igfpjkhk; gapj;jpaj; jpy;yhjkpQ;rpg; 
ghukha; cw;gtpj;JmoYz;lhFk; 
ca;fpjkhk; mrdkJjhDk; Ntz;lh 
cjputhjRNuhzpjj; Jzh;r;rpahNk. 
Characterized by pain and swelling in both ankle joints, knee joints and all smaller 
joints of the hand, feeling of tiredness, fever loss of appetite and mental depression. 
Also causes swan neck deformity and wasting of thenar muscle in rheumatoid 
arthritis.           
2. According to PARA RASA SEKARAM: 
gf;fKk; khh;Gk; $lg;gw;wpNa ,Oj;Jf; nfhz;L  
nef;fpNakhh;gpisj;JNjhjha; euk;gpOj;J 
xf;fNtrapj;jpaq;fs; cah;e;Jld; NkYk; fhyk; 
kpf;FNkcjputhjk; vd;wpJtpsk;gyhNk 
     - guuhrNrfuk 
It is characterized by pain and tenderness of the axilla, breathlessness, pain in 
the upper limbs and the lower limbs. 
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SIDDHA PATHOLOGY 
TRI-DOSHAM THEORY: 
SYNONYMS: mukkuttram, muppini. 
Tridosham is the principle or concept of tamil siddha medicine system. When 
these dosham are in de-arranged manner causes various types of diseases. These three 
dosham play vital role in deciding a person’s physical and mental qualities. Vatham, 
pittam and kabam are formed by the combination of one or two mahabhootas: 
Vatham - ether + air 
Pittam – agni 
Kabam – water + earth  
Normal ratio of vatham, pittam,kabam is 1 : ½ : 1/4. The ethics and attitude of 
siddha system says that human body is the replica of the universe. 
In uthiravathasuronitham the vatham is in increased manner. The increased 
vathakuttram causes vitiation of other two kuttrams[ pittam and kabam],  which inturn 
results in the manifestation of a disease. 
DISEASE: 
A disease is a particular abnormal condition,  a disorder of a structure or 
function, that  affects a part  or all  of an organism.The study of a disease is  known as 
pathology. 
SYNONYMS: sickness, distemper, suffering, affliction, distress of mind. 
THE CHARATERISTIC FEATURE OF A DISEASE: 
Disease can be classified into two kinds. They are : 
¾ Pertaining to the mind. 
¾ Pertaining to the body according to the variation of the three humors. 
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DIAGNOSIS 
“Neha;ehbNeha;KjdhbaJjzpf;Fk; 
  tha;ehbtha;g;gr; nray;” 
                            jpUf;Fws 
According to thiruvalluvar , in thirukural explains the importance of diagnosis 
as it is to be made inorder of the aetiology, root cause of the disease thereby treating 
the disease with appropriate medicine. 
PINIYARI MURAIGAL [ METHODS OF DIAGNOSIS] : 
Mainly depends upon the three principles. They are: 
¾ Poriyalarithal [ inspection] 
¾ Pulanalarithal [ palpation] 
¾ Vinaathalarithal [ interrogation] 
 
1. PORIYALARITHAL: 
Poriyalarithal is nothing but examining the patient by direct perception. Pori is 
considered as the “ five sense organs” of perception. They are namely : 
¾ Mei [skin] 
¾ Vai [tongue] 
¾ Kan [eye] 
¾ Mookku [nose] 
¾ Sevi [ear] 
2. PULANALARITHAL: 
pulanalarithal is examination of the patient by using senses. They are : 
¾ Smell  
¾ Taste   
¾ Vision 
¾ Sensation of touch [ palpation] 
¾ Hearing 
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3.VINAATHALARITHAL: 
Vinaathal is collecting information regarding the history of disease, its 
symptoms, etc, from the patient. 
 
DIAGNOSTIC METHODOLOGY IN SIDDHA SYSTEM OF MEDICINE: 
1. ENVAGAI THERVUGAL [ EIGHT DIAGNOSTIC TOOLS]: 
These methods not only help in the diagnosis but also helps to detect the 
prognosis of the disease and for convincing the patient and to be informed about the 
nature of disease. They are: 
x Naadi [pulse] 
x Sparisam [ sensation to touch] 
x Naa [ tongue] 
x Niram[color] 
x Mozhi [voice] 
x Vizhi [eyes] 
x Malam [faeces] 
x Moothiram [ urine] 
ehb ];ghprk; ehepwk; nkhoptpop 
kyk; %j;jpukpitkUj;JtuhAjk;. 
                                   - Neha; ehly; Neha; Kjy; ehly; (Kjy; ghfk;) 
 
”nka;f;Fwpepwk; njhdptpopeh ,Ukyk; iff;Fwp” 
    - Njiuah; 
¾ NAADI [PULSE] : 
 
Naadi is defined as the pulse wave as felt on the radial artery, one inch from 
the wrist by means of palpation with the tip of index, middle and ring finger 
corresponds to vatham,pitham and kabam. They normally exsist in the ratio 1 : 
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½ : ¼ respectively. Naadi is the first and foremost diagnostic parameter of the 
siddhars. The commonly seen naadi in uthiravadhasuronitham are: 
 
x Vathapitham 
x Pithavatham 
x Vathakabam 
 
 In uthiravathasuronitham, vatha is increased, followed by an increase in other 
two kutrams ie.,pitham and kabam. 
 
jpUj;jkhk; thjj;NjhNljPq; nfhLgpj;jQ; Nrhpy; 
nghUj;Jfs; NjhWk; nehe;J  
- Fzthflk; Nehapd; rhuk; 
fhzg;ghthjkPwpy; 
fhy; iffs; nghUj;JNehFk; 
- fhtpaehb 
thjj;jpd; FzNknjd;dpy; 
tapwJnghUkpnfhs;Sk; 
jhjj;jpd; Nkdp if fhy; 
re;JNkfLg;Gj; Njhd;Wk;” 
- Fwpailahsehb. 
¾ SPARISAM [TOUCH] : 
 
The examination regarding skin is made by inspection and palpation. It 
declare about the warmth / chillness, dry / weeping skin , rough / smooth , soft 
/ hard , tenderness, presence of ulcers, fissures, swelling, wrinkles, etc. 
             In uthiravathasuronitham mild warmth is felt over the affected joints 
with swelling, tenderness and subcutaneous nodules and the degree of warmth 
may vary from one another depending on the severity of disease. 
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¾ NAA [ TONGUE]: 
 
The colour, character and condition of tongue are noted. In uthiravathasuronitham 
tongue  commonly  does  not  show  any  abnormality.  In  case  with  anaemia  it  may  
appear pallor, glossy and coated. 
 
¾ NIRAM [COLOUR]: 
 
Signs of different complexions in vatham, pittam, kabam and thontha thegis, 
cyanosis, pallor, yellowish discolouration may be noted. 
In uthiravathasuronitham no abnormalities are seen normally. Sometimes pallor of 
skin may be noted incase of anaemia and redness seen in inflamed joints. 
 
¾ MOZHI [VOICE] : 
 
It constitutes high, low-pitched voice, nasal speech, hoarseness of voice, 
slurring and incoherent speech etc.In uthiravathasuronitham no abnormalities are seen 
normally. 
¾ VIZHI [EYES]: 
Both  motor  and  sensory  disturbance  of  eye  are  noticed.  Redness  of  eyes,               
paleness, excessive lacrimation, swelling, corneal ulcers, sunken eyes may be noted. 
In uthiravathasuronitham no abnormalities are seen normally. In anaemic patients 
pale conjunctiva may be noted. 
¾ MALAM [FAECES]: 
 
x Vatham: black coloured stools along with constipation. 
x Pitham  : loose stools with yellowish red color 
x Kabam : white coloured stools with mucous 
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x Thontha  :  stools  contains  some  of  the  features  of  two  
thodams. 
Constipation was reported in some case of 
uthiravathasuronitham. 
¾ MOOTHIRAM [URINE]: 
 
Neerkuri and neikuri[oil on urine sign] are special diagnostic methods 
regarding urine [moothiram]. 
 
NEERKURI[ PHYSICAL EXAMINATION OF URINE]: 
jpUj;jkhk; thjj;NjhNljPq; nfhLgpj;jQ; Nrhpy; 
nghUj;Jfs; NjhWk; nehe;J 
- Fzthflk; Nehapd; rhuk; 
fhzg;ghthjkPwpy; 
fhy; iffs; nghUj;JNehFk; 
- fhtpaehb 
thjj;jpd; FzNknjd;dpy; 
tapwJnghUkpnfhs;Sk; 
jhjj;jpd; Nkdp if fhy; 
re;JNkfLg;Gj; Njhd;Wk;” 
- Fwpailahsehb. 
The urine is collected and examined for the following: 
x Niram–colour 
x Edai – specific gravity 
x Manam – smell  
x Nurai – frothy nature 
x Enjal – deposits / quantity of urine voided. 
In uthiravathasuronitham straw or hay coloured urine is noticed in neerkuri. 
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NEIKURI [OIL ON URINE SIGN] : 
In uthiravathasuronitham the patterns of neikuri is “aravenaneendathuvatham”. In 
some  cases  the  oil  drop  remain  as  that  of  a  pearl  or  ring  indicating  kabaneer  or  
pithaneer accordingly. 
1. THINAI: 
         
There are five thinai [ the land ]. 
 
S.NO THINAI AFFECTED HUMORS 
1 Kurinchi Kabam 
2 Mullai Pitham 
 3 Marutham All 3 humors are in equilibrium 
4 Neithal Vatham 
5 Palai All 3 humors are affected. 
 
NEITHAL : 
         nea;jdpy; NtYtHg;igePq;fhJwpDkJ 
 nta;jdpyNkjq;FtPlhFk; - neha;jPd; 
 kUq;FliyKf;fhf;fpty;YWg;igtPf;Fk; 
 fUq;Fliyf; fPopwf;Fq; fhz; 
- gjhHj;jFzrpe;jhkzp 
In neithal [costal area] vatham is being more predominant, and since 
uthiravathasuronitham being a vatham predominant disease seem as to occur more in 
neithalnilam. It is being worsened in palainilam and increased in marutham nilam. 
2. KAALAM: 
Generally a year is divided into 6 months called as perumpozhuthu and a day 
into 6 segments called as sirupozhuthu during ancient period. 
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PERUMPOZHUTHU: 
 
s.no season  Months  Kuttram 
1 Kaarkaalam August 16 – October 
15 
Vatham ĹĹ 
Pitham Ĺ 
2 Koothirkaalam October 16- 
December 15 
Vatham [-] 
Pitham Ĺ 
3 Munpanikaalam December 16- 
feburary 15 
Pitham [-] 
4 Pinpanikaalam Feburary 16- april 15 Kabam Ĺ 
5 Elavenirkaalam April 16 – june 15 Kabam ĹĹ 
6 Mudhuvenirkaalam June 16 – august 15 Vatham Ĺ 
Kabam [-] 
 
Ĺ - Thannilaivalarchi 
ĹĹ - vetrunilaivalarchi 
[-] – thannilaiadaithal 
 
Uthiravathasuronitham may occur in kaarkaalam and it may get worsen badly 
in muthuvenilkaalam. 
SIRUPOZHUTHU: 
A day is divided into 6 yamas. They are: 
x Maalai [ evening] 
x Idaiyammam [ midnight] 
x Vaikarai [ dawn] 
x Kaalai [ morning] 
x Nannpakal [ noon] 
22 
 
x Erpaddu  [ afternoon] 
¾ uthiravathasuronitham  may worsen in vaikarai and kaalai [ morning 
stiffness]. 
¾ Maalai [ evening] – manifested with fever 
¾ Nannpakal and erpaadu – subside slightly. 
 
MUKKUTRAM 
Synonyms: Tridosham ,muppini 
Tridosham is the principle or concept of tamil siddha medicine system. When 
these doshas are in de-arranged manner causes various types of diseases. These three 
doshas play a vital role in deciding a person’s physical and mental qualities. vatham 
,pittam and kabam are formed by the combination of one or two mahabhootas. They 
are  
x Vatham – ether + air 
x Pittam – agni 
x Kabam – water + earth 
 
Normal ratio of vatham, pittam and kabam is 1: ½ : ¼. The ethics and attitude of 
siddha system medicine says that human body is the replica of the universe. 
VATHAM: 
Vatham governs all movement in the mind and body. It controls blood flow, 
elimination of waste, breathing and movement of thoughts across the mind. Vatham 
derives from elements of space and air. Vatham is nothing but the energy of 
movement and the drive governing all biological activity. Vatham is considered as the 
“king of the doshas”, since it maintains the body’s greater life force and helps in the 
movement of pittam and kabamdosham. Vatham is considered as the king who rules 
the body [ fort]  and enables the well-being of the citizens [ uyir]. 
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SITES OF VATHAM: 
According to vaidyachatakam, the sites of vatham are: umbilicus, rectum, 
faecal matters, abdomen, anus, bones, hip joints, skin, navel, plexus, hair follicles and 
muscles.According to saint tirumoolar and yugi muni, the sites of vatham are : anus 
and below the navel region. 
TYPES OF VATHAM: 
According  to  siddha  classical  texts,  the  vatham  is  classified  into  10  types  
based on their location and function. They are : 
x Praanan 
x Abaanan 
x Viyaanan 
x Samaanan 
x Naagan 
x Koorman 
x Kirukaran 
x Dhevathathan 
x Dhananjeyan 
 
FUNCTIONS OF VATHAM: 
Functions of vatham are as follows: 
x Responsible for respiration. 
x Regulates defaecation, micturition, ejaculation, etc 
x Responsible for natural physiological reflexes like vomiting, 
sneezing, hiccup, cough, etc. 
x Helps in digestion and medication. 
x To strengthen five sense organs. 
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x To activate body, mind and intellect. 
 
IN CASE OF UTHIRAVATHASURONITHAM: 
The following types of vatham are being affected. They are: 
x Abaanam – causes constipation 
x Viyaanam – produces restricted movements 
x Samaanan - affected due to the derangements of four Vatham humour 
x Kirukaran – produces loss of appetite 
x Dhevathathan – insomnia. 
PITHAM: 
The pittam is considered as bio energy fire. 
SITES OF PITTAM: 
                According to vaidyasathagam, the sites of pittam are- urinary bladder, 
stomach and heart. Umbilicus, epigastric region, sweat, saliva, blood, essence of food, 
eyes etc are also considered as the sites of pittam. 
                  According to yugi muni, the sites of pittam are urine, region below the 
neck region. 
TYPES AND FUNCTIONS OF PITTAM: 
              There are 5 types of pittam. They are: 
x Analapittam – considered as fire of pittam. 
x Ranjagapittam – haematinic fire 
x Saathagapittam – fire of achievement 
x Prasakapittam – fire of brightness 
x Alosagapittam – fire of vision. 
INCASE OF UTHIRAVATHASURONITHAM: 
x Analapittam – causes loss of appetite 
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x Ranjagapittam – pallor due to Hb 
x Saathagapittam – difficulty in walking, climbing upstairs, squatting. 
x Prasakapittam – skin pallor.                                                                                              
KABAM: 
Kabam is considered as the bio-energy water. Synonym of kabam is iyyam. 
SITES OF KABAM: 
              The sites of kabam are head, tongue, eyes, nose, throat, thorax, bone, bone 
marrow, joints, blood, fat, sperm and colon. 
TYPES AND FUNCTIONS OF KABAM: 
x Avalambagam – nodal 
x Kiletahgam – digestive 
x Pothagam  – taste 
x Tharpagam  – coolant 
x Santhigam  - articulant 
 
INCASE OF UTHIRAVATHASURONITHAM: 
x Kilethagam – loss of appetite 
x Santhigam – restricted movements of joints 
UDAL KATTUGAL: 
Udalkattugal is nothing but the seven physical constituents of the body. They are: 
x Saaram– gives physical and mental immovability. 
x Senneer – admits colour to the body and nourishes the body. 
x Oon– gives shape to the body according to the physical activity 
x Kozhuppu–  anoints  the  joints  and  other  parts  of  the  body  for  smooth  
functioning. 
x Enbu– supports the body frame and responsible for the postures and 
movements of the body. 
26 
 
x Moolai– involves the medulla of the bones and gives strength and softness 
to them. 
x Sukkilam / suronitham– responsible for reproduction. 
Incase of uthiravathasuronithamsaaram, seneer, oon, kozhuppu, enbu and moolai are 
mainly affected. 
SAARAM: 
x Increased vascular congestion. 
x Aggression of synovial layers by polymorphs, lymphocytes, plasma 
cells. 
x Thickening of capsular structure. 
x Villous formation of synovium 
x Cell-rich effusion into joints and tendon sheaths. 
x Generation of synoviocytes. 
SENNEER : 
x RBC and WBC abnormalities 
x Increased ESR 
x Decreased haemoglobin 
x Increased lymphocytes 
x Increased IgG antibody 
x Increased HLA-DR4 
OON : 
x Tenosynovitis 
x Swelling 
x Invasion of collagen bundles 
x Partial or complete rupture of tendons 
KOZHUPPU: 
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x Attacks the synovial membrane surrounding the lubricating fluid 
in the joints. 
x Morning stiffness occurs in affected knee joints. 
x Loss of sufficient lubrication that produces friction in between 
the bones of joints. 
ENBU : 
x Pain occurring in affected knee joint, crepitation present. 
x Bone is eroded by granulation tissue invasion and 
osteoclasticresorption 
MOOLAI : Anaemia 
DIFFERENTIAL DIAGNOSIS 
UthiravathaSuronitham is differentiated from other types of VathaSuronitham 
as follows: 
thjRNuhzpjk; 
 “mwpe;jpl;lmq;fnky;yhnkypTkhfp 
  mirthdjt;tplq;fs; tPf;fkhfp 
 ewpe;jpl;leilnfhlhjhdpUj;jy; 
  eypahfpnkhopnkhopatPf;fkhfr; 
 nrhwpe;jpl;NlNjfnkq;FkirTfhzy; 
  Nrhw;wpd; Nkdpidtpd;wpj; J}f;fkhjy; 
 twpe;jpl;lthajdpdPHjh D}wy; 
  thjRNuhzpje;jhDk; tFj;jthNw”. 
VATHA SURONITHAM 
 Emaciation. 
 Swelling of joints. 
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 Restricted movements. 
 Joint pain. 
 Discomfort. 
 Excessive salivation. 
 Loss of appetite. 
rpj;JthjRNuhzpjk; 
 “thwhdrhPunky;yhEioe;JCjy; 
  khrw;wNjhy;jhDe; jpiue;JNghFk; 
 ehwhdehWNghy;euk;GRf;Fk; 
  ehf;Fj;jhd; totoj;Jf; NfhioahFk; 
E}whdneUg;Gj;jhd; gl;lhw; Nghy 
  nehe;JNkrlnky;yhk; nfhg;gspf;Fk; 
 tPwhdThpe;Jgpd;idntJk;gptPq;Fk; 
  kpf;frpj; JthjRNuhzpjkjhNk”. 
SITHUVATHA SURONITHAM 
 Anasarca. 
 Wrinkles. 
 Neural pain. 
 Glossy tongue. 
 Sialorrhoea. 
 Bullous eruption as in burn. 
 Exfoliation, swelling  andWarmthness. 
 
gapj;jpathjRNuhzpjk; 
 “czHr;rpaha; RNuhzpje;jhd; kpfnt Jk;gp 
  Cf;fkha;j; Njfnkq;F kpfNt nehe;J 
 KzHr;rpaha; Koq;fhy;fs; Koq;if nahf;f 
  Kidahd rpWtpuy;fs; fd;dk; new;wp 
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 jzHr;rpaha; re;JrU thq;f nkq;Fk; 
  jh\;bfkha;f; File;J RuK Kz;lhk; 
 gzHr;rpaha;g; ghz;lJNghy; Nkdp ahFk; 
  gapj;jpa thjRNuhzpjj;jpd; gz;G jhNd”. 
 
PAITHIYA VATHA SURONITHAM 
 Hyperaemia. 
 Tenderness in knee, elbow and smaller joints. 
 Poly arthralgia. 
 Pyrexia. 
 Anaemia. 
 
Nrj;JkthjRNuhzpk; 
“gz;ghf Tly;FspHe;J VW tPq;fpg; 
 gijg;ghd tple;njhl;lhw; ghu Nehthk; 
jpz;ghd rpuRnew;wp Nehf;fh Lz;lhk; 
 rpNyl;L kkha;f;Nfhio nahLR thrkhFk; 
kz;ghf kaf;f nkhL fdT Kz;lhk; 
 tha;tuz;L Urpapy;yh tUj;j khFk; 
ez;ghf ehbANk gl glf;Fk; 
ew;Nrl;g RNuhzpjkhk; ehLq; fhNy”. 
 
SLETHUMAVATHA SURONITHAM 
 Chillness with abdominal distension. 
 Severe pain and Head ache. 
 Syncope and Hallucination. 
 Dryness of mouth and Anorexia. 
 Tachycardia. 
cjuthjRNuhzpjk; 
 “ehLNk Ruk;te;J eLf;f Yz;lhk; 
  ehtuz;L jiynehe;J clk;g Oj;jp 
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 thLNk Njfnky;yh kdpr;rg; G+g;Nghy; 
  kfhtUj;j Kz;lhfp kaf;f khFk; 
 rhLNk abf;fbjhd; Ngjp jhDk; 
  jtpf;FNk jz;zPHjh dhl;l khfpj; 
 NjLNk Nrhw;wpd;Nky; epidT jhDk; 
  nraTju thjRNuhzp je;jh ndd;Nd”. 
UTHARAVATHA SURONITHAM 
  Fever with rigor. 
 Dryness of mouth. 
 Pain in all over the joints. 
 Headache. 
 Diarrhoea. 
 Excessive thirst. 
 Hunger. 
 
itfpjthjk; 
 “Mnkd;w tPq;fpdNjhH tplj;jpy; uj;jk; 
  mOj;jkha;j; jpuz;LNk vq;Fk; gha;e;J 
 Xnkd;W Xl;bNajp uz;b Uf;Fk; 
  cWjpaha;j; njhl;LlNd nkj;njd; whFk; 
 Njnkd;w Njfnkq;f ZK Rf;Fk; 
  rPwpa NjhhpUknyhL fhr;r Yz;lhk; 
 ghnkd;w gle;jdpNy jpkpUz; lhFk; 
  ghukha; itfpjkhk; thje; jhNd”. 
-  A+fp itj;jpa rpe;jhkzp 
 
UthiravathaSuronitham is differentiated from other types of VathaSuronitham 
as follows: 
VAIKITHA VATHA SURONITHAM 
 Swelling with hyperaemia. 
 Soft on touch. 
 Cough with pyrexia. 
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 Irritability. 
LINE OF TREATMENT IN SIDDHA SYSTEM OF MEDICINE: 
 
x In siddha system of medicine,the treatment is based on following  
strategy as follows 
x Kaapu(prevention) 
x Neekam(curing) 
x Niraivu(restoration) 
KAAPU(PREVENTION):             
        
          
                 Its goal is to protect, protect and maintain health and well being and to  
prevent disease, disability and death. Preventive  measures were classified into two 
types as follows  
x Nithiya ozhukkam 
x Kaala ozhukkam           
   
 
 
        NITHIYA OZHUKKAM means daily routine which we do in day to day cycle 
such as 
x Morning wake up 
x Bath 
x Diet 
x Sleep. 
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        KAALA  OZHUKKAM  means  things  which  are  carryout  according  to  the  
seasonal variation for healthy living. 
        In siddha system of medicine prevention very well priorlized. 
 
NEEKAM: 
     The treatment in SIDDHA SYSTEM OF MEDICINE is followed on the basis of 
PANCHA BOOTHA THEORY such as MUKKUTTRAM-ARUSUVAI. 
    The relationship between PANCHA BOOTHAM,MUKKUTTRAM AND 
ARUSUVAI  is described in the following table: 
MUKKUTRAM PANCHA BOOTHA KOOTU 
Vatham Vin+vaayu 
Pitham Neruppu 
Kabam Man+neer 
 
ARUSUVAI PANCHA BOOTHA KOOTU 
Inippu Man+Neer 
Pulippu Man+Neruppu 
Thuvarppu Man+Neer 
Uvarppu Neruppi+Neer 
Kaarpu Neruppu+Vaayu 
Kaippu Vaayu+Vin 
                                                  
From the above table,we can conclude the following points: 
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x The Inippu(sweet),Pulippu(sour),Uppu(salt) decrease the vatha kutram. 
x The Kasappu(Bitter),Inippu(Sweet),Thuvarppu(Astringent) decreases 
the pitha kutram, 
x The Karppu(purgent),Kasappu(bitter),Thuvarppu(astringent) decreases 
the kaba kutram, 
The physician will treat the diseases by normalizing the deranged 
uyirthathu.So the treatment is based on: 
x To bring the mukkutram to balanced state. 
x Treat the disease according to the symptoms, 
x To intensify the natural immunity. 
                            
 
NIRAIVU: 
Life style modification was advised to the patients about the awareness of 
diet,season,emotional influence based on disease state. 
MANAGEMENT OF UTHIRAVATHASURONITHAM: 
             Among the 80 vatha disease,uthiravathasuronitham is one among them.For  
vatha diseases,PURGATION is given to stabilize them. 
 10ml Vellai ennai is given in early morning, on the very first day of treatment 
for purgation. 
            The second day,patient is advised to take rest on that full day.  
            From the third day onwards,patient is advised to take the trial drug. 
TRIAL DRUG: 
INTERNAL MEDICINE : 
GANDHAGA RASAYANAM: 
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Reference : AthmaratchamirthamVaithyasarasangraham,pg no:438 
Dose   :500mg, twice a day. 
Adjuvant : Hotwater 
Duration : 48days  
EXTERNAL MEDICINE : 
NAVANATHASITTHA THAILAM: 
Reference : Theren thaila varga surukkam  (Pg.No:133) 
Dose   : 25ml for external use. 
PATHIYAM: 
                Siddha system of medicine have specific diet regimen based on disease 
affected and body constitution of the patients. Diet plays major role in enhancing 
curing capacity of medicine.           
 
         “gj;jpaj;jpdhNy gyd; cz;lhFk; kUe;J 
 gj;jpaq;fs; Nghdhy; gyd; NghFk; 
 gj;jpaNk ntw;wp jUk; gz;bjHf;F Mjypdhy; 
 gj;jpaNk cj;jpnad;W ghH” 
- Njud; ntz;gh 
During the course of treatment, the patients were advised to follow certain diet 
regimen (Icha pathiyam) which is mentioned for vatha diseases. 
1. Kadugu        - Brassica nigra (Mustard seed) 
2. Ell Nei         - Gingelly oil 
3. Poosanikkai - Bennicasa hispida 
4. Kadalai        - Arachis hypogea 
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5. Thengai       - Coccus nucifera 
6. Mangai        - Mangifera indica 
7. Poondu       - Allium sativum 
8. Pala             -  Artocarpus heterophyllus 
9. Kollu           - Horse gram 
10. Pugaiyilai   - Nicotiana tobaccum 
11. Pagal          - Momordica charantia 
12. Agathi         - Sesbania grandiflora 
13. Sour taste 
14. Astringent taste 
SUBSTANCES USED FOR NEUTRALIZING THREE HUMOURS  ARE: 
“xd;wpa thjgpj;j fgkpit Aauh tz;zk; 
ed;wW fwp fnsy;yhk; ehSNk rikg;guha;NjhH 
jpd;wpL kpsF kQ;rs; rPuf KaHe;j fhak; 
ntd;wp nfhs; Rf;NfhNlyk; nte;jpak; cs;sp NrHNj” 
- g.F.rp 
TO MAINTAIN THREE VITAL HUMOURS IN EQUILIBRIUM ONE SHOULD 
TAKE FOOD COOKED WITH 
Pepper  - Piper nigram 
Turmeric   - Curcuma longa 
Cumin seeds -  Cuminum cyminum 
Asafoetida  - Ferula asafoetida 
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Dry ginger  - Zingiber officinale 
Cardamom  - Elettaria cardamom 
Fenugreek   - Trigonella foneum 
Garlic          - Allium sativum 
SUBSTANCES ADVISED FOR VATHA DISEASES ARE : 
 
“nrq;fOePH Nfhilj; Njd; kpsF ey;nyz;iz 
jq;F ngUq;fhaj; jOjhio - vq;nfq;Fk; 
fl;L rpW Kj;J nea; Nfhjpy; cSe;Jitfs; 
thl;L kzpyf;if kjp”  
- g.F.rp 
x Honey collected during summer 
x Pepper          -        Piper nigram 
x Gingelly oil  - Sesamum indicum 
x Asafoetida  - Ferula asafoetida 
x Castor oil    - Riccinus communis 
x Black gram - Vigna mungo 
x Garlic  - Allium sativum 
NrHf;ff; $ba czTfs;: (Diet to be included) 
fha;fs; (Vegetables): 
¾ fj;jhpg;gpQ;R  - Unripe brinjal 
¾ KUq;ifg; gpQ;R  - Unripe drumstick 
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¾ mtiug;gpQ;R  - Unripe broadbeans 
fPiufs;(Greens): 
¾ nghd;dhq;fz;zp   - Alternanthera sessilis 
¾ %f;fpul;il    - Boerhaavia diffusa 
¾ JhJNtis    - Solanum trilobatum 
¾ KUq;iff;fPiu      - Moringa oleifera 
¾ fwpNtg;gpiy          -    Murraya koenigii 
¾ Klf;fWj;jhd;          -         Cardiospermum halicacabum 
¾ mWfPiu              -          Amaranthus tristis 
¾ fhprhiy             -          Eclipta prostrate 
goq;fs;(Fruits): 
¾ khJis  -  Pomegranate 
¾ Mg;gps;   - Apple 
¾ gg;ghsp   - Papaya 
¾ MuQ;R    -  Orange 
¾ NghPr;ir   - Dates 
¾ mj;jp    -  Figs 
¾ ehty;    -  Syzygium cumini 
mirtk; (Non-Vegetarian diet): 
¾ nts;shl;Lf;fwp  -Meat 
¾ fhil  -      Quail
¾ rpW ,why; kPd;  -Prawn 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
                  MODERN ASPECT 
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RHEUMATOID ARTHRITIS:  
HISTORY: 
    AB Garrod in 1858 named the disease rheumatoid arthritis replacing the old terms 
arthritis deformans and rheumatic gout. He is thus credited to make a distinction 
between rheumatoid arthritis and OA and gout. 
       Appearance of rheumatoid arthritis affected joints was first described by  
Bannatyne 1896. It was in 1940 that Camroe coined the term rhematologist and  the 
term rheumatology was coined by Hollander in 1949. 
                                                               Webresults:Rheumatoid arthritis history. 
                                                                                              By Dr.Ananya mandal MD 
                                                                                                    www.news-medical.net         
GENERAL CONSIDERATION: 
Rheumatoid arthritis [RA] is one of the most common chronic inflammatory 
arthritis affecting 0.5-1.0% of the general population world wide. Epidemiology 
surveysby WHO-COPCORD[ world health organization community oriented 
program for control of rheumatic diseases] shows a prevalence of 0.45% in urban 
india and 0.7% in rural population. RA in india is predominantly with arthritic 
manifestations with lower frequency of extra articular features and rheumatic nodules. 
The frequency of positive rheumatoid factor [RF] varies from45% in rural community 
to 80% in the hospital setting. The frequency of antibody to anti cyclic citrullinated 
peptide[ anti- CCP] positivity in this survey varies from 59-100%.  RA in the Indian 
rural sitting is much more disabiling and is related to work conditions and methods 
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and popular. Indian customs of squatting and sitting cross legged in floor. The disease 
is  3  times  more  common  in  women  than  men  with  a  peak  incidence  in  3rd and  4th 
decades. 
 
 
ETIOLOGY : 
RA is multifactorial in its etiology consisting of genetic and environmental 
factors. Interaction of these factors cause altered post- transcriptional regulation and 
self- protein citrullination leading to loss of self-tolerance. 
GENETIC FACTORS: 
Overall the contribution of genetic factors is to the order of 10-15%. The 
strongest genetic association is with the class II major histocompatibility complex 
[MHC] gene containing the susceptibility epitope [SE] which is a specific 5 amino 
acid sequence in the hyper variable region of human leukocyte antigen [HLA]- DR4 
presence of SE causes a 4-5 fold increase  of risk of developing RA. Recently other 
genes  like  PTPN,  PADI,are  also  found  to  increase  the  risk  of  RA  by  two  fold  ,  
suggesting that the genetic association of RA are complex and may involve many 
genes. 
Environmental factors: 
Many environmental triggers like smoking, infection, chronic gingival disease, 
diet and hormonal factors can precipitate RA in genetically susceptible persons. 
1. SMOKING is a strong stimulus for protein citrullination and generation of 
anti  CCP  antibodies.  The  SE  has  increased  ability  to  bind  to  citrullinated  
protein.  A  smoker  with  two  copies  of  HLA-SE  has  40  fold  chance  of  
developing RA than a non smoker without HLA-SE. 
2. INFECTIONS by viruses like Epstein barrvirus, parvovirus and 
chickungunya virus can act as a triggering agent to develop RA. Chronic peri-
odonitis is found to be risk factor for RA as the bacteria 
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porphyromonasgingivalis, commonly associated with this disease stimulate 
protein citullination and development of auto-antibodies of RA. 
3.HORMONAL FACTORS: 
Breast feeding increases the risk of RA due to the surge of pro-inflammatory 
hormone prolactin. Nulliparity also found to increase the risk of RA. 
 
 
 
PATHOLOGY: 
RA is an auto immune disease of unknown etiology. It evolves through a 
multistep pathogenic process starting with break in self- tolerance with production of 
antibodies to anti-CCP. There is increased production of proinflammatory cytokines 
like tumor necrosis factor- alpha [TNF-Į ], interleukin-1 [II,-I] , interleukins-6 [II,6] 
etc, which leads to influx of immune cells into the synovial compartment. This 
process results in synovial cell proliferation and angiogenesis which leads into the 
formation of pannus.  
The pannus consists of fibroblasts like synoviocytes mixed with macrophages 
surrounding newly formed blood vessels, enzymes like proteases and elastases 
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released by the cells in the pannus, cause cartilage erosion. The pro- inflammatory 
cytokines like TNF-Į, II-I, II-6, activate the osteoclast causing bone erosions. 
The articular cartilage is eventually destroyed with loss of joint space. Fibrosis 
develops across the joint space to produce ankylosis. The joint is deformed and 
secondary degenerative changes develop. Infection may supervene in these joints to 
convert them into septicarthritis. 
 
 
 
EXTRA-ARTICULAR LESIONS: 
Other tissues are affected to varying degrees. Basic pathology is the same as in 
the synovium. Lesions are seen in the skin, lungs, heart, liver, nervous system and 
eyes. The small blood vessels may be affected. They show intimal hyperplasia, 
perivascular round cell infiltration and occasionally necrotizing panarteritis. 
Subcutaneous nodules consist of a central area of fibrinoid necrosis surrounded by 
mono nuclear cells arranged in a palisade manner. 
42 
 
 
 
 
CLINICAL FEATURES: 
Females  are  more  prone  than  males  in  a  ratio  of  3:1.  The  disease  is  more  
common in the 4th and 5th decades. The disease passes through different stages: 
x Onset to 6 months- early RA. 
x 6months to 2 years – established RA. 
x Above 2 years – advanced RA. 
Early symptoms are nonspecific and they include undue fatigability, weight 
loss, poor appetite, transient myalgias and parasthesia. 
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ARTICULAR INVOLVEMENT: 
The onset is generally insidious and the disease presents as a chronic symmetrical 
polyarthritis.  Less common presentation include: 
x Acute polyarthritis 
x Oligo arthritis 
x Acute monoarticular arthritis 
x Chronic monoarticular arthritis 
x Systemic disease with fever, sweating, leukocytosis and pleural effusion 
in addition to arthritis. 
Any diarthrodial joint may be inflamed. Arthralgia, arthritis, muscle wasting, 
tendonitis, tendon rupture and deformities constitute the main lesions. The affected 
joints are warm, painful and swollen. Movements are restricted, especially in the 
morning after sleep [ morning stiffness] and after the periods of resting. Classic 
findings are seen in the joints of the hands and feet, metacarpophalangeal [MCP], 
metatarsophalangeal [MTP] and proximal interphalangeal [PIP] joints are inflamed 
most frequently. Wasting of the small muscles of hand may develop due to disuse and 
direct muscle involvement. 
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In  the  hands,  there  is  typical  ulnar  deviation  of  the  MCP  joints  and  wrists.  
Sometimes, there is anterior subluxation of metacarpal heads and medial dislocation 
of the extensor tendons. Swan neck deformity of the fingers consists of 
hyperextension of the PIP joints and flexion of the distal interphalangeal joints. This 
deformity impairs effective handgrip. Sometimes, the extensor expansion overlying 
the PIP joint ruptures resulting in the dorsal protrusion of the head of the proximal 
phalanx. This leads to flexion of the PIP joint and hyper extension of the distal 
interphalangeal joint deformity. 
The extensor tendons may undergo attrition, these result in loss  of extension 
of the fingers [ dropped fingers]. Large joints like the knees, wrists, ankles, elbows, 
and shoulders may also be involved. Tense synovial effusions may develop in the 
knees. Baker’s cysts are tense  cysts developing in the popliteal fossae as a result of 
collection of synovial fluid.  
These may occasionally rupture giving rise to a painful and tender swelling on 
the calf.  Lateral  subluxation of the knee joint  is  also very common. Chronic arthritis  
develops which leads to permanent deformities. Deformities are also common in the 
feet. Hammer toe is flexion at the PIP joint and hyper extension at the MTP 
joint.Hallux valgus may also develop. The arches of the feet may be lost due to 
affection of the joints and ligaments. Callosities develop over prominent bony points. 
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Less commonly, the cervical spine and temporo mandibular joints are 
affected, but when they occur, the lesions are characteristic. At the atlanto axial joint, 
the transverse ligament of the atlas may be weakened leading to atlantoaxial 
subluxation.This leads to pain in the neck and pain refered to the temporal and retro- 
orbital regions. There may also be a clunking sound in the neck on flexion. It is 
dangerous to manipulate the neck to elicit this sign. Atlantoaxial subluxation produces 
a host of neurological manifestations. 
 
The risk of sudden compression of the spinal cord is high in such subjects. 
Hence, tracheal intubation and similar procedures, which require manipulation of the 
neck should be done only with caution. Temporomandibular arthritis leads to pain 
on mastication. Other portions of the spine, such as the dorsolumbar regions and 
sacroiliac joints are usuallynot affected in RA. 
TISSUE INVOLVEMENT IN RA: 
SYSTEMIC INVOLVEMENT: 
EXTRA-ARTICULAR MANIFESTATIONS 
Skin:    painless and nontender subcutaneous nodules ranging in size from a 
few  millimeters  to  a  few  centimeters  develop  around  the  extensor  aspects  of  the  
elbow and other subcutaneous bony surfaces and over tendons in 20-30% of cases. 
They  are  almost  always  associated  with  a  positive  serology.  They  persist  for  
considerable periods. Involvement of blood vessels gives rise to raynaud’s 
phenomenon, vasculitis of the nailbeds and finger pulps, nonhealing ulcers of the 
finger, palmar erythema and hyperhidrosis of the extremities. 
Eyes : ocular lesions develop in a few cases and these may become disabiling 
nodular. In necrotizing scleritis, the nodules degenerate and the underlying dark uvea 
imparts a blue color. Sometimes the sclera may be thickened due to granuloma 
formation. Perforation of the sclera leads to prolapse of the uvea and eventual rupture 
of the globe [SCLEROMALACIA PERFORANS]. 
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In the cornea, band keratopathy may develop. This is more frequent in 
stillsdisease. Though the sclera is affected, it is rare to involve the iris. Lesions of the 
iris are more frequent in seronegativearthropathies. 
Respiratory system:cricoarytenoid arthritis manifests as dysphonia, stridor or 
dyspnea. Recurrent pleural effusion may occur which is usually unilateral. 
Rheumatoid nodules may develop in the lungs and these maycaviate. 
Interstitialfibrosis may develop and this may be indistinguishable from the idiopathic 
type. 
Caplan’s syndrome:is a special phenomenon occurring in subjects with 
rheumatoid disease who develop pneumoconiosis. Large coalescing nodules develop 
in the lungs. These are demonstrable by x-rays. 
Cardiovascular system:it is only rarely involved. Lesions include 
pericarditis, mitral/aortic regurgitation and conduction defects. There is increased 
incidence of artherosclerosis and ischemic heart disease with higher mortality in RA. 
Nervous system: neurological involvement is not uncommon in chronic cases. 
Entrapment neuropathy such as carpal tunnel syndrome and tarsal tunnel syndrome, 
may be the presenting lesions or they may develop during the course. Symmetrical 
polyneuropathy develops which improves with treatment. Mononeuritis multiplex 
also occur in severe cases of rheumatoid disease and leads to foot drop or wrist drop. 
These are generally resistant to treatment. Cervical cord compression due  to  
atlantosublaxation is a less common complication in long-standing RA. Mild cases 
present with transient neck pain radiating to the back of the head. It can rarely lead to 
subluxation of the odontoid process with compression of the cord which may end 
fatally. Progressive clinical myelopathy at a lower level may develop insidiously. 
This is characterized by gradual onset of limb weakness, inability to hold the head 
erect and quadriparesis. The lesion is due to subluxation at lower levels of the cervical 
cord. 
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Renal involvement: Type-Irenal tubular acidosis and analgesics neuropathy can 
rarely occur. 
Secondaryamylodiosisis a late complication in some cases of chronic 
rheumatoid disease. 
Laboratory investigations: 
Erythrocyte  sedimentation  rate  [ESR]  is  markedly  raised  in  the  disease  and  
may exceed 100mm/hour in the majority. Normochromic normocytic anemia, iron- 
deficiency anemia or rarely hemolytic anemia may be present in the acute phase. 
Serum protein electrophoresis may show elevation of Į and Ȗ- globule 
Ins. C-reactive protein [CRP] will also be high. 
SEROLOGY: 
Rheumatoid factor : 
Antibodies in rheumatoid disease, especially the immune- globulin M [IgM], 
can be demonstrated by the rose-waaler test, latex filtration test or nephelometry. 
RF is positive in 70-80% of adults with RA. tn 20-30% of cases antinuclear 
antibodies may be demonstrable. To establish seropositivity, the test should be 
positive atleast on two occasions separated by 3-6 months. If negative, it should be 
repeated atleast once more after 6-12 months. Five to ten percent of normal 
individuals, especially elderly, may show RF positivity in low titers. 
 
Antibody to anti- cyclic citrullinated peptide 
It is a new antibody test for the early diagnosis of RA. Formations of anti-CCP 
antibodies are highly specific for RA patients. Anti-CCP antibodies are present early 
in erosions change in bone. 
Antinuclear antibody 
Anti nuclear antibody [ANA] of unknown specificity may be positive in 30% 
of RA. 
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SYNOVIAL FLUID ASPIRATION: 
This reveals a turbid fluid with low viscosity and poor mucin clot. The whita 
cell count in the fluid exceeds 1500/mm. The cells are mostly neutrophils even though 
the synovial membrane is not infiltrated by them. Complement levels are low. The 
protein content will also be high. 
RADIOLOGY : 
Characteristic lesions, which have been graded from I to IV, are seen 
radiological study. 
x Grade I: soft tissue swelling which indicates synovitis 
with or without juxta- articular osteoporosis which 
indicates active inflammation. 
x Grade II:narrowing of joint space due to cartilage 
destruction. 
x Grade III:erosions which may be of two types:  
                         1.surface erosion at joint margins.  
                         2. Cystic erosion of the bone shaft. 
x Grade IV: marked irregularity of articular surfaces 
with subluxation and secondary degenerative changes. 
Bony ankylosis occurs only very rarely. 
DIAGNOSIS : 
The diagnosis is to be made on clinical examination and laboratory criteria. 
Since, clinically several conditions resemble RA, new diagnostic criteria have been 
laid down by the joint committee for American college of rheumatology [ACR] and 
European league againt rheumatism [EULAR] in 2010. This score is based on : 
x Joint involvement 
x Autoantibody status 
x Duration of joint symptoms. 
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             A score with six or more points supports the diagnosis of RA. Patients with 
typical bony erosion or long standing disease previously satisfying the criteria can 
also be labelled as RA. 
DIFFERENTIAL DIAGNOSIS: 
                      RA has to be distinguished from rheumatic arthritis in which children 
are more affected, the joint lesions are migratory, large joints are affected, effusions is 
prominent and ASO titre is high [ > 1/200 todd units]. 
Psoriatic arthritis: 
In psoriatic arthritis, there is invariabily evidence of psoriasis of the skin or nails and 
the arthritis involves the small joints of the hands and feet more. The hand may be 
severly multilated[ arthritis mutilans]. Involvement of the sacroiliac joints and spine 
is not uncommon. 
Gout: 
         Several joints may be affected in gout. The MTP joint of the big toe is 
characteristically affected more frequently, though any joint may be involved. In 
chronic tophacdeous gout, tophi may be seen as nodules around the joints, especially 
the elbow. 
Osteo arthritis: 
            It affects elderly subjects. Most common joints affected are the spine, hips, 
knees and distal interphalangeal joints.Heberden’s nodes may be seen at the base of 
the  distal  phalanges.  The  condition  is  progressive  .  The  ESR is  generally  normal  or  
only mildly elevated. In many cases, rheumatoid and osteo arthritis may co-exsist in 
different joints. 
OTHER CONDITIONS: 
                           Other conditions which may mimic RA are syphilitic arthritis, 
gonococcal arthritis, reactive arthritis and ankylosing spondylitis. In ankylosing 
spondylitis, the sacroiliac joints and spine are maximally affected. Pheripheral joint 
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involvement is less common and predominantly involves large joints of lower limb[ 
knees, ankles and hips]. 
                    In india several other conditions should be considered when the clinical 
presentation and investigation are not helpful straight away. These include allergy to 
tuberculosis [poncdet’s disease], serum sickess like reactions, reactions in leprosy, 
drug –induced arthralgias, infections such as chikungunya, brucellosis, joint 
tuberculosis, human immunodeficiency virus [HIV] infection and many others. 
PROGNOSIS: 
           In general, the disease tends to become recurrent and chronic and in many 
cases it leads to considerable disability and deformity. Severe RA shortens life. It 
tends to severe impairment of the quality of life. A third of the patients with RA 
deteriorate clinically by consumption of food particles such as trout, fishes, peas, 
carrot, bottled mineral water, sea salt, milk, dairy products, wheat, coffee, chocolate, 
citrus fruits, corn and others. Free amino acids and oligopeptides contained in some of 
them are weakly antigenic and they may be responsible for this adverse effect. 
COMPLICATIONS – EXTRA ARTICULAR MANIFESTATIONS: 
Systemic: 
x Fever 
x Weight loss 
x Fatigue 
x Susceptibility of infection. 
 
Vasculitis: 
x Digital arteritis 
x Ulcers 
x Pyodermagangrenosum 
x Mononeuritis multiplex 
x Visceral arteritis 
Musclo skeletal: 
x Muscle wasting 
x Tenosynovitis 
x Bursitis 
x Osteoporosis 
Cardiac: 
x pericarditis 
x myocarditis  
x endocarditis 
x conduction defects 
x coronarvasculitis 
x granulomatous arthritis 
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Haemotological : 
x anaemia 
x thrombocytosis 
x eosinophilia 
Nodules: 
x sinuses 
x fistula 
Lymphatic: 
x splenomegaly 
x lymphadenopathy 
x felty’s syndrome 
 
Pulmonary: 
x nodules 
x pleural effusion 
x fibrosingalveolitis 
x bronchiolitis 
x caplan’s syndrome 
Ocular: 
x episcleritis 
x scleritis 
x scleromalacia 
x kerato conjunctivitis sicca 
Neurological : 
x Cervical cord compression 
x Compression neuropathies 
x Peripheral neuropathy 
x Mononeuritis multiplex 
x Amyloidosis 
 
RHEUMATIC VARIANTS: 
JUVENILE IDIOPATHIC ARTHRITIS (JIA): 
It  is  the  most  common  cause  of  chronic  arthritis  in  childhood.  This  term  
encompasses all idiopathic arthritis affecting children below 16 years of age and 
lasting for more than 6 weeks. This may be oligo- or polyarticular. In the 
oligoarticular types lower limb joints-knees, hips, 
ankles and tarsal joints are affected asymmetrically. In the polyarticular type 
both small and large joints are affected, usually in a symmetrical manner. The clinical 
features may be confined to the skeletal system, but in 10% the onset and course are 
characterized by systemic manifestations such as high fever (>38.5°C) transient 
erythematous rash, generalized lymphadenopathy, hepatosplenomegaly, anemia and 
weight loss. Fever is intermittent with periods of normal temperature in between, 
during which the child appear to be normal. The serious complications include 
macrophage activation syndrome characterized by onset 
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of thrombocytopenia, anemia, liver dysfunction and rapid downhill course which may 
end fatally. 
STILL’S DISEASE : 
(CHRONIC JUVENILE POLYARTHRITIS) : 
This disorder occurs before the age of 16 years. Girls are affected more than 
boys. It differs from adult rheumatoid disease in that the disease is more often 
pauciarticular.Rash, fever, mphadenopathy, and splenomegaly are characteristic. 
Subcutaneous nodules are rare and rheumatoid factor is negative. Eye involvement 
with uveitis and keratopathy is more common. The treatment is along the same lines 
as for adult rheumatoid arthritis. 
FELTY’S SYNDROME : 
This is seen in older age groups. In addition to the classic features of 
seropositive rheumatoid arthritis, splenomegaly and neutropenia also occur. 
Splenomegaly may lead to hypersplenism. Splenectomy may have to be considered to 
correct hypersplenism, in addition to treatment for the rheumatoid state. 
SJÖGREN’S SYNDROME (SS) : 
This is a chronic inflammatory autoimmune disease characterized by mixed 
cellular infiltration of the exocrine glands, particularly the lachrymal and salivary 
glands- a form of autoimmune exocrinopathy (autoimmune epithelitis). This results in 
dryness of the eyes (xerophthalmia), dryness of the mouth (xerostomia) and 
frequently, dryness of the nose, throat and vagina. This condition predisposes to 
increased risk of mucosaassociated lymphoid tissue lymphoma MALT lymphoma). 
SS may be primary in which it is the only demonstrable abnormality. Secondary SS, 
known  also  as  sicca  complex  may  be  associated  with  any  of  the  other  autoimmune  
diseases. Radiation therapy of the head and neck for Hodgkin’s disease, sarcoidosis, 
amyloidosis and tuberculosis may lead on to SS. 
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PALINDROMIC RHEUMATISM : 
In this condition repeated attacks of joint pains, redness and swelling occur. The 
attacks occur suddenly within hours and may affect one joint usually. The affected 
joint shows signs of inflammation. These last for a few days and subside without any 
residual lesions. The ESR is raised during the attacks and remains high even during 
the intervals. After varying periods of time, typical rheumatoid arthritis supervenes in 
many cases, whereas spontaneous remission occurs in some patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIAL AND METHODS 
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MATERIALS AND METHODS 
 The Evaluation on Uthiravatha Suronitham was carried out in the OPD and 
IPD of the Sirappu Maruthuvam department, Govt. Siddha Medical College, Chennai.  
 STUDY DESIGN & CONDUCT OF STUDY: 
STUDY TYPE : An open Pilot study 
STUDY PLACE : OPD & IPD of Govt.Siddha Medical College & 
Hospital, Chennai. 
STUDY PERIOD : 12 Months 
SAMPLE SIZE  : 40 patients (20 OP+20 IP).out of 20 op patients treated 
with internal alone and 20 IP patient treated with internal and external medicine. 
TREATMENT : 
INTERNAL MEDICINE : 
GANDHAGA RASAYANAM: 
Reference : AthmaratchamirthamVaithyasarasangraham,pg no:438 
Dose   :500mg, twice a day. 
Adjuvant : Hotwater 
Duration : 48days  
EXTERNAL MEDICINE : 
NAVANATHASITTHA THAILAM: 
Reference : Theren thaila varga surukkam  (Pg.No:133) 
Dose   : 25ml for external use 
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INCLUSION CRITERIA : 
x Age : 18-60 years 
x Sex : Both Male and Female 
x Symmetrical joint involvement 
x Arthritis of 3 or more joints 
x Rheumatoid factor positive or negative 
x CRP positive 
x AntiCCP positive 
x Morning stiffness 
x Swelling especially in the inter Phalangeal joint. 
x Patients who are willing for admission and stay in ipd for 48 days or willing to 
attend OPD 
x Patient who are willing to undergo radiological investigation and give blood 
and urine samples for laboratory investigation. 
x Patient willing to sign the informed consent stating than he/she will 
consciously stick to the treatment during 48 days but can opt out of the trial of 
his/her own conscious discretion. 
EXCLUSION CRITERIA : 
x Hypertension and other cardial ailments. 
x Diabetes  mellitus 
x Rheumatic fever 
x Narcotics 
x Alcoholics and smokers 
x Pregnancy and lactation 
x History of sulphur allergy 
x Tuberculosis 
x Any other serious illness 
x Psoriatic arthropathica 
x Gouty arthritis 
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WITHDRAWAL CRITERIA : 
x Intolerance to the drug and development of adverse reactions during drug trial. 
x Poor patient compliance and defaulters. 
x Patient turned unwilling to continue in the course of clinical trial. 
x Occurrence of any adverse reactions.  
TESTS AND ASSESSMENT : 
A. Clinical assessment 
B. Routine investigations 
C. Specific investigations 
D. Radiological  investigations 
E. Siddha investigations  
A. CLINICAL ASSESSMENT : 
x Arthritis involving three or more joints(with or without soft tissue 
involvement lasting more than 6 weeks) 
x Symmetrical arthritis(atleast one area lasting for 6 weeks) 
x Morning stiffness 
x Anorexia 
x Spindle shaped appearance of fingers 
x Rheumatoid nodules 
x Depression 
x Radiographic changes 
B. ROUTINE INVESTIGATION : 
BLOOD: 
 Hb 
 Total WBC count 
 DC – Polymorphs 
1. Lymphocytes 
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2. Eosinophils 
3. Monocytes 
4. Basophils 
Total RBC Count 
ESR 
 ½ Hr 
 1 Hr 
Blood Sugar  
 R: 
 F: 
 PP: 
Serum cholesterol. 
URINE 
 Albumin  
Sugar (F) 
(PP) 
Deposits 
Kidney Function tests 
 Urea 
 Creatinine 
Liver function tests 
 Serum Total bilirubin 
 Direct bilirubin 
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 Indirect bilirubin 
 Serum Alkaline phosphatase 
 SGOT 
 SGPT 
C. SPECIFIC INVESTIGATIONS 
 CRP 
 RA factor 
            ASO titre 
          AntiCCP 
D. RADIOLOGICAL INVESTIGATIONS : 
 X Ray of affected joints (Ap and Lateral view) 
E. INVESTIGATION BASED ON SIDDHA SYSTEM : 
1. Naa 
2. Niram 
3. Mozhi 
4. Vizhi 
5. Naadi 
6. Sparisam 
7. Malam 
8. Moothiram 
9. Neikuri 
10. Neerkuri 
DATA COLLECTION FORMS: 
 Required information will be collected from each patient by using the 
following forms 
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FORMS: 
 
FORM I  : Screening and Selection Proforma 
FORM I A  : History Proforma on Enrollment 
FORM II  : Clinical assessment on enrollment 
FORM II A  : Clinical assessment during and after trial 
FORM III  : Laboratory Investigation on enrollment and conclusion  
of trial 
FORM  IV   : Consent Form 
FORM IV B  : Withdrawal form 
FORM IV C  : Patient information sheet 
FORM IV D  : Dietary Advice form 
FORM IV E  : Adverse Reaction form 
FORM IV F  : Discharge proforma 
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PATIENT SCREENING 
 
INCLUSION CRITERIA 
EXCLUSION CRITERIA 
 EXCLUDED FROM TRIAL 
METHODOLOGY 
STUDY NUMBER 
HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
TREATED IN OPD 
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
INFORMED CONSENT FORM 
 
ADVERSE EFFECT 
TREATED IN OPD REFERRAL 
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STUDY ENROLLMENT: 
Patients reporting at the OPD of Govt. siddha medical college and hospital, 
Chennai.with the clinical symptoms of fatigue, weekness, vague arthralgia, myalgia 
,joint stiffness are choosen for enrolment based on  the inclusion and exclusion 
criteria.  
 The patients who are to be enrolled would be informed (form IV) about the 
study, trial drug, possible outcomes and the objectives of the study in the language 
and terms understandable to them. 
 After ascertaining the patient’s willingness, informed consent would be 
obtained in writing from them in the consent form (form IV).  All these patients will 
be given unique registration card in which patient’s registration number of the study, 
address, phone number and doctor’s phone number etc., will be given, so as to report 
easily should any complications arise. 
 Complete clinical history, complaints and duration, examination findings—all 
would  be  recorded  in  the  prescribed  proforma in  the  history  and  clinical  assessment  
forms separately.  Screening Form – I will be filled up.   Form – II and form – III will 
be used for recording the patient’s history, clinical examination of symptoms and 
signs and laboratory investigations respectively.  Patients would be advised to take 
the trial drug and appropriate dietary advice (Form IV-D) would be given according 
to the patients perfect understanding.  
CONDUCT OF THE STUDY: 
 10ml  of  Vellai  ennai  is  given  in  early  morning,  on  the  very  first  day  of  
treatment for purgation. This will help to bring the vitiated mukkutram back to 
normal. From the next day, the trial drug is given for treatment.  
                  The trial drug will be given in the OPD department of PG sirappu 
maruthuvam, GSMC, Chennai. The patients will be asked to have a regular follow up 
in the OP department once in 2 days. In each and every visit the clinical assessment 
will be recorded in the prescribed proforma. The laboratory investigation will be done 
before and after treatment and recorded in the prescribed format.  
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DATA MANAGEMENT: 
 After enrolling the patient for the study, a separate file for each patient will be 
maintained  and all forms will be kept in the file.  Study No. and Patient identity No. 
will be written on the top of file for easy identification.  Whenever study patient visits 
OPD during the study period, the respective patient file will be taken and necessary 
enteries will be made at the assessment form or other suitable form.  The screening 
forms will be filed separately.  The data recordings will be monitored by HOD and 
pharmacovigilance committee.  All forms will be further scrutinized in presence of 
Investigators with concerned Department faculties for logical errors and 
incompleteness of data to avoid any bias.  No modification in the results is permitted 
for unbiased report. 
OUTCOME: 
 The outcome is by comparing the reduction of symptoms before and after 
treatment. 
UNIVERSAL PAIN ASSESSMENT SCALE 
A.   A .0     : No Pain 
B. 1 -3 :  Mild pain 
C. 4-6   :  Moderate pain 
 D. 7-10 :  Severe pain 
                          - Reference: Clinical Manual for Nursing Practice. ( National 
Institute of Health Warren Grant Magnuson Clinical Center )  
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Restricted movements is assessed by  
GRADATION OF RESTRICTED MOVEMENTS : 
x G I – Able to perform normal duties 
x G II – Moderate Restriction – Self care is possible. 
x G III – Marked restriction – Limited self care / Some assistance required. 
x G IV – Confined to bed or wheel chair.  
ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT 
             If the trial patient develops any adverse reaction, he/she would be refered 
tothe pharmacovigilance department of SCRI and documented .For any adverse effect 
the investigator will give the proper management in the OPD. 
ETHICAL ISSUES: 
x To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of laboratory 
equipments will be used.     
x No other external or internal medicines will be used, other than the trial drug 
for uthiravatha suronitham. There will be no infringement on the rights of 
patient. 
x The data collected from the patient will be kept strictly confidential. The 
patient will be informed about the diagnosis, treatment and follow-up. 
x After getting the consent of the patient (through consent form) they will be 
enrolled in the study. 
x Treatment would be provided free of cost. 
              In  conditions  of  any  treatment  failure  or  adverse  reactions,  patients  will  be  
given       alternative treatment at the Govt. Siddha Medical College & hospital, 
Chennai.with full care throughout the end. 
 
 
 
 
 
 
 
 
 
 
TRIAL DRUG 
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TRAIL DRUG PREPARATION : 
INTERNAL MEDICINE : 
GANDHAGA RASAYANAM: 
Reference : AthmaratchamirthamVaithyasarasangraham,pg no:438 
(Rathna naickar and sons) 
Dose   :500mg, twice a day. 
Adjuvant : Hot water 
Duration :48 DAYS 
 INGREDIENTS: 
S.no Tamil name Botanical name Quantity 
1 Thirikaduku Zingiber officinalae 
Piper nigrum 
Piper longum 
16.8gm 
each 
2 Kirambu Syzygium aromaticum 16.8gm 
3 Elam Elattaria cardamomum 16.8gm 
4 Elavanghapattai Cinnamomum verum 16.8 gm 
5  Elavanghapatri Cinnamomum tamale 16.8 gm 
6  Sathikkai Myristica fragrans henlt 16.8 gm 
7 Omam Carum copticum 16.8gm 
8 Jeerakam Cuminum cyminum linn 16.8 gm 
9 Poonaikkali Mucuna pruriens linn. Dc  16.8 gm 
10 Neermulli Hygrophylla auriculata 16.8 gm 
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11 Nerunjil Tribulus terrestris linn 16.8 gm 
12 Ashwagandhi 
kizhanghu 
Withania somnifera linn 16.8 gm 
13 Kumkuma poo Crocus sativus linn 16.8 gm 
14 Sathipathri Myristica fragrans henlt 16.8 gm 
15 Thiripalai Terminalia chebula 
Terminalia bellarica 
Embelica officinalis 
16.8 gm 
16 Perichampalam Phoenix  sylvestris 16.8 gm 
17 Kothamalli Coriandrum sativum 16.8 gm 
18 Sadamanjil Nardostachys grandiflora Dc 16.8 gm 
19 Athimadhuram Glycyrrhiza glabra linn 16.8 gm 
20 Thakkolam  16.8 gm 
21 Candanam Santalum album linn 16.8 gm 
22 Munthirikkai Anacardium  occidentale linn 16.8 gm 
23 Karunjeerakam Nigella sativa linn 16.8 gm 
24 Paranghipattai Smilax chinensis linn 700 gm 
25 Aanaithippili Scindapsus officinalis schott 16.8 gm 
26 Thippili moolam Piper longum 16.8 gm 
27 Citramoolam Plumbago indica linn 16.8 gm 
28 Kurosaani omam Hyoscyamus niger linn 16.8 gm 
29 Vilamichhu veer Plectranthus vettiveroides  16.8 gm 
30 Sirunagha poo Mesua nagassarium kosterm 16.8 gm 
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31 Talisa patri Abies spectabilis mirb 16.8 gm 
32 Poolangkizhangu Curcuma zedoaria rosc 16.8 gm 
33 Vettiver Vetiveria zizanoides linn 16.8 gm 
34 Tanner vittan 
kizhanghu saru 
Asparagus racemosa willd 7.8 l 
35 Koovai neer Maranta arundinaceae linn 16.8 gm 
36 Nilapanai kilanzhu Curculigo orchioides 16.8 gm 
37 Muthakkasu Cyperus rotundus linn 16.8 gm 
38 Sitrathai Alpinia galangal linn 16.8 gm 
39 sarkarai Sugar 2450 g 
40 gandhagam Sulphur 140 g 
41 then Honey 1.3 l 
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DESCRIPTION OF INTERNAL MEDICINE: 
S.
n
o 
Tamil 
name 
Botani
cal 
name 
& 
family 
Vern
acula
r 
name 
Chemical 
compositi
on 
Parts 
used 
Suvaa
i 
Tanmai Pirivu Actions 
1 Kiramb
hu 
Syzygi
um 
aromat
icam 
Myrtac
eae 
Hin- 
laung 
Eng- 
clove 
San-
lavan
ga 
Eugenol, 
furfural, 
vanillin, 
methyl 
alcohol, 
methyl 
benzoate 
Clov
e oil, 
flowr
al 
bud 
Karpp
u 
veppam karppu Antispas
modic,c
arminati
ve,stom
achic 
2 Elam Elettari
a 
cardam
om 
zingibe
raecea
e 
Hin-
choti 
ilaich
i 
Eng- 
lesser 
carda
mom 
San- 
ela 
Bornneol, 
camphene, 
linalool, 
myrcene, 
methane, 
heptane. 
Seeds Karpp
u 
Veppam Karppu Stimulta
nt., 
carminat
ive, 
stomach
ic 
 
3 Lavang
ha pattai 
Cinna
momu
m 
zeylani
ca 
laurace
ae 
Hin-
dalchi
ni 
Eng- 
cinna
mon 
San- 
tvak 
Eugenol, 
methyl 
amyl 
ketone, 
cymene, 
borneol 
Bark Kaara
m, 
enipp
u, 
thuvar
ppu. 
Veppam Karppu Carmina
tive, 
haemost
atic 
4 Lavang
ha 
pattiri 
Cinna
momu
m 
tamala 
nees 
Laurac
eae 
Hin-
teja 
patra, 
San- 
patra 
Eugenol, 
linalool, 
cinnamic 
aldehyde 
Leaf Enipp
u, 
karpp
u 
Veppam karppu Carmina
tive 
5 Saathik
ai 
Myristi
ca 
fragran
Hin-
jaipha
l 
Safrole, 
elemin, 
cyanadin, 
Fruit Thuva
rpu 
karpp
Veppam Karppu Stimula
nt, 
carminat
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s henlt 
Myristi
caceae 
Eng- 
nutm
eg 
San-
jatiph
ala 
nectandrin, 
trimyristin 
u ive, 
narcotic, 
aromatic
, 
aphrodis
iac 
6 Omam Carum 
copticu
m 
benth
& 
hook 
Umbel
liferrae 
Hin-
ajamo
da 
Eng-
bisho
ps 
seed, 
San-
yavan
i 
Luteolin, 
apigravin, 
apiin, 
anthoxanth
ins, 
sedanolide 
Seed Karpp
u 
Veppam Karppu Stomach
ic, anti 
spasmod
ic, 
carminat
ive, 
antisepti
c, 
stimulan
t 
7 Jeeraka
m 
Cumin
um 
cymin
um 
Umbel
liferae 
Eng-
cumi
num 
seeds, 
San- 
jeerak
a 
Cuminin, 
apigenin, 
Oxalic, 
apiin, 
imperatori
n, p-
cymene 
Seed Karpp
u 
Veppam Enippu Carmina
tive, 
stimulan
t, 
astringe
nt, 
stomach
ic 
8 Poonaik
aali 
Mucun
a 
prurien
s linn 
Fabace
ae 
Hin- 
kavac
h, 
eng- 
com
mon 
cowit
ch, 
san- 
kapik
acchu 
Mucunine, 
prurienine, 
stearic, 
palmitic, 
myristic, 
sterol, 
choline 
Seed, 
root 
Thuva
rppu, 
Tatpam Enippu Astringe
nt, 
nervine 
tonic, 
aphrodia
siac, 
vermifu
ge, 
irritant 
9 Neermu
lli 
Hydro
phylla 
auricul
ata 
Acanth
aceae 
Hin-
talma
khana
, 
Eng-
long 
leave
d 
barler
ia, 
san- 
Hygrophil
oside 
Flow
er, 
seed 
Enipp
u 
Tatpam Enippu Demulc
ent, 
diuretic, 
refrigera
nt, 
aphrodis
iac 
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kokil
aksha 
1
0 
Nerunjil Tribul
us 
terrestr
is linn 
Zygop
hyllace
ae 
Hin-
gakhr
u 
Eng-
small 
caltro
ps 
San- 
goksh
ura 
Chlorogeni
n, 
diosgenin, 
rutin, 
trillin, 
furostanol 
glycoside 
Whol
e 
plant 
Thuva
rppu, 
enipp
u 
Seetam Enippu Refriger
ant, 
diuretic, 
aphrodis
iac, 
astringe
nt 
1
1 
Aswake
nthi 
kilangh
u 
Withan
ia 
somnif
era 
linn 
Solana
ceae 
Hin-
asgan
dha 
Eng-
winte
r 
cherr
y 
San- 
aswa
gandh
a 
Withafein, 
somnirol, 
somnitol, 
nicotine, 
tropine, 
solasodine 
Leaf, 
seed, 
root 
Kaipp
u, 
Veppam Karppu Febrifug
e, 
diuretic, 
aphrodis
iac, 
deobstru
ent, 
soporifi
c, 
sedative 
1
2 
Kumku
ma poo 
Crocus 
sativus 
linn 
Hin-
kumk
um 
kesar 
Eng- 
saffro
n, 
san- 
kunk
uma 
Crocin-
1,2,3,4; 
esters of 
crocetin, 
picrocin, 
crosatoside
s 
Stam
ens / 
stigm
a 
Kaipp
u 
Veppam Karppu Stimula
nt, 
stomach
ic, 
anodyne
, anti 
spasmod
ic, 
emmena
gogue 
1
3 
Saati 
patri 
Myristi
ca 
fragran
s henlt 
Myristi
caceae 
Hin-
javatr
i 
Eng- 
arillu
s of 
the 
nut 
San-
jatipa
ȕ pinene;Į 
terpinene; 
Myristicin; 
trimyristin; 
myristic 
acid; 
cyanadin; 
neolignans 
Seed; 
seed 
coat; 
Oil 
Karpu
; 
Thuva
rpu; 
vetpam Karpu Aphroid
siac; 
Carmina
tive; 
Stimula
nt; 
Hypnoti
c 
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tri 
1
4 
Thiripal
a 
Termin
alia 
chebul
a, 
combr
etaceae 
Termin
alia 
bellari
ca, 
combr
etaceae 
Embell
ica 
officin
alis, 
euphor
biacea
e 
 
Hin- 
Thiri
pala 
Eng-
Three 
Myro
balan
s 
San- 
Triph
ala 
 Fruit Thuva
rpu; 
Vetpam Karpu Astringe
nt 
1
5 
Pericha
mpazla
m 
Phoeni
x 
Sylvest
ris 
Roxb 
Arecac
eae  
Hin- 
Kharj
ur 
Eng-
Dates 
Palm 
San- 
Kharj
ura 
 Fruits
, Leaf 
Eenip
u 
Seetham Eenipu  
1
6 
Kotham
ali 
Corian
drum 
Sativu
m Linn 
Apiace
ae  
Hin-
Dhan
ya 
Eng- 
Coria
nder 
Seeds 
San-
Dhan
yaka 
Carotene; 
Bergapten; 
Coriandrin
d; 
Coriandrin
;Citronello
l; 
Coriandron
e A& B 
gnaphalosi
des A&B 
Leaf; 
Seed 
Karpu Seetha 
Vetpam 
Karpu Stomach
ic; 
Carmina
tive; 
Stimula
nt; 
Diuretic 
1
7 
Sadaa 
Manjal 
Nardos
tachys 
gradifl
Hin- 
Jatam
asi 
Actinidein
e; 
Carotene; 
Aristolens; 
Root Eenip
u 
Vetpam karpu Stimula
nt; 
Antispas
modic; 
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ora DC 
valeria
naeae 
 
Eng- 
Valer
ina 
Root 
San- 
Jatam
ansi 
Elemol; 
Jatamols 
A&B; 
Jatamansic 
Acid; 
Nardostach
onol; 
Nardol; 
Virolin; 
Spirajatom
ol 
Diuretic
; 
Expecto
rant 
1
8 
Athimat
huram 
Glycyr
rhiza 
glabra 
Linn 
Fabace
ae  
Hin-
Jathi 
Madh
;  
Eng-
Jamai
ca 
Liquo
rice 
San-
yasti
madh
u 
Glycyrrhiz
in; 
Glycyrrhiz
ic Acid; 
Liquirtin; 
Isoliquirtin
; 
Glabranine
; 
Glabrolide; 
Hispaglabr
idin A & B 
Licoricidin 
Root Eenip
u 
Vetpam Karpu Emollie
nt; 
Demulc
ent; 
Laxative
; Mild 
Expecto
rant; 
Tonic 
1
9 
Thakkol     Thuva
rpu 
Vetpam Karpu Anti-
Vatha; 
Astringe
nt; 
Febrifug
e; 
Nutritiv
e 
2
0 
Sandana
m 
Santal
um 
album 
linn 
Santala
ceae  
Hin- 
Chan
dan 
Eng-
Sanda
l            
Wood 
San-
Chan
dana 
Į 
santol;ȕsan
tene & 
Santalenes; 
teresantalo
l; nor-
tricycloeka
santalal; 
Santanone; 
Tere 
Santalic 
Acid 
Mara
m; 
Oil 
Kaipp
u; Siru 
Thuva
rpu 
Vetpam; 
Thitpam 
Eenipu
; Karpu 
Alternat
ive; 
Diuretic
; 
Diaphor
etic; 
Stimula
nt; 
Disinfec
tant; 
Astringe
nt; 
Cooling 
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2
1 
Muthiri
kkai 
Anacar
dium 
Occide
ntale 
Linn 
Hin-
Kaju 
Eng-
Cashe
w Nut 
Tree 
San- 
Shop
hakar
a 
 Fruits
; 
Seed; 
Bark 
Fruit- 
enipp
u 
Bark- 
thuvar
ppu 
Fruit-
tatpam 
Bark- 
tatpam  
Fruit- 
enippu 
Bark- 
thuvarp
pu 
Palam-
Diuretic
;Stimula
nt; 
Pattai- 
Astring
ment; 
Vithai- 
Tonic; 
Aphrodi
siac 
 
2
2 
Karun 
jeeraka
m 
Nigella 
sativa 
Linn 
Ranun
culace
ae 
Hin- 
Kulan
ji 
Eng- 
Black 
Cumi
n 
San- 
Upak
anchi
ka 
Poisonous 
Saponin; 
Melanthin 
BitterAlkal
oid; 
Cymine; 
Carvone;Li
monene; 
Nigellin 
Seed Kaipp
u 
Vetpam Karpu Carmina
tive; 
Diuretic
; 
Emmen
agogue; 
Stomach
ic 
Galacto
gogue; 
Anthelm
intic; 
Parastici
de; 
Emollie
nt 
2
3 
Parangi 
patti 
Smilax 
china 
Linn 
Liliace
ae 
Hin-
Chob
chini 
Eng-
China
Root 
San-
Madu
snuhi 
Shikimic 
Acid; 
Ferulic 
Acid; 
Smilaxin; 
ȕSitosterol
; 
Engeletin; 
Astilbin 
  
Tube
r 
Eenip
u 
Tatpam Eenipu Alterati
ve; 
Antisyp
hilitic; 
Aphrodi
sac; 
Depurati
ve 
2
4 
Aanai 
thipillai 
Scinda
psus 
officin
alis 
Schott 
Aerace
ae  
Hin- 
Boai-
Pipli  
San- 
Gaja-
Pippa
li 
Sitosterol, 
piplartine. 
  
Seed 
Karpp
u 
Vetpam Karppu Stomach
ic; 
Stimula
nt; 
Anthelm
intic; 
Sudorifi
c 
(Diapho
retic) 
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2
5 
Thipili
moolam 
Piper 
longu
m 
Pipera
ceae  
Hin- 
Felfel
ai-
Maya 
Eng- 
Long 
Peppe
r 
Root 
San- 
pippa
li 
mool
am 
Essential 
Oil; 
Piperine; 
ȕsitosterol; 
Cepharadi
ones 
Root Eenip
u 
Vetpam Eenipu Stomach
ic 
2
6 
Citra 
Mulam 
Plumb
ago 
indica 
linn 
Plumb
aginac
eae 
 Chitratnon
e, 
plumbagin, 
droserone, 
elliptinone, 
zeylinone, 
maritone, 
plumbaghi
c acid 
Root, 
bark 
Karpp
u 
Veppam Karppu Stomach
ic 
stimulan
t, tonic, 
caustic, 
vesicant
diaphore
tic 
2
7 
Kurosaa
ni 
omam 
Hyosc
yamus 
niger 
Linn 
Solana
ceae  
Hin-
Khor
asani-
Ajao
wan 
Eng- 
Black 
Henb
ane 
San- 
Parasi
ka 
Yava
ni 
Apoatropin
e; 
Hyoscine; 
Tropine; 
Hyoscine-
N-Oxide; 
Aphoyosci
ne 
Seeds Karpp
u 
Vetpam Karppu Hypnoti
c; 
Sedative
; 
Anodyn
e; Anti 
Spasmo
dic; 
Mild 
Diuretic 
2
8 
Vilaami
chai Ver 
Plectra
nthus 
vettive
roides 
(Jacob) 
Singh 
& 
Sharm
a 
Hin- 
Eng-
White 
Cus 
Cus 
Grass 
San- 
Hribe
 Root Kaipp
u 
Seetham Eenipu Refriger
ant; 
Anti 
pittha 
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Lamen
aceae  
ram 
2
9 
Sirunag
a poo 
Mesua 
nagass
arium 
(Burm.
f) 
Koster
m 
gutifer
aceae 
 
Hin- 
NagK
esara 
Eng- 
Ceylo
n 
Lorn 
Wood 
San- 
Naga
Kesar
a 
Mesual; 
Mammegi
n; 
Bioflavono
ne-
Mesuaferr
ona; 
Cyclohaxo
dione;ȕam
yrin 
Leaf, 
Flow
er, 
Seed, 
Root, 
Bark 
Siruka
ippu; 
Thuva
rpu 
Thatpa
m 
Karppu Poo- 
Astringe
nt; 
Carmina
tive 
Kaai- 
Aromati
c; 
Acrid; 
Purgativ
e 
Pattai-
Mild 
Astringe
nt 
3
0 
Thaalisa
pathiri 
Abies 
specta
bilies 
(D.Do
n) 
Mirb 
Pinace
ae  
Hin-
Talis
patra
m 
Eng- 
Many 
Spike
d 
Flaco
rtia 
San- 
Talki
saPat
hra 
Abiesin; n-
triacontano
l; 
Betuloside; 
ȕsitosterol; 
A 
bioflavono
id 
Leaf Karpp
u 
Vetpam Karppu Stomach
ic; 
Carmina
tive; 
Expecto
rant; 
Tonic 
3
1 
Poolang
h 
kizhang
u 
Curcu
ma 
zedoari
a Rose 
Zingib
eracea
e  
Hin- 
Kach
ur 
Eng-
Roun
d 
White 
Zedar
y 
San- 
Kach
ura 
  Leaf, 
Tube
r 
Kaipp
u 
Vetpam Karppu Stimula
nt; 
Carmina
tive; 
Expecto
rant; 
Diuretic
; 
Alternat
ive; 
Aromati
c 
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3
2 
Vetiver
u 
Vetive
ria 
zizanoi
des 
Linn 
Grami
naceae  
Hin-
Khas 
Eng-
Khas
khas 
Grass 
San-
Ushir
a 
Benzoic 
Acid; 
Euugenol; 
Khusimon
e; 
Cyclocapa
camphene; 
ȕEudesmol
; Vanillin; 
Zizaene; 
Vetivenic 
Acid; 
Epizizanal 
Root Enipp
u 
Seetham Karppu Coolent, 
anti 
pitta 
3
3 
Thanner 
vittan 
kizhang
u charu 
Aspara
gus 
racena
sus 
Wild 
 
Hin-
Satav
are 
Eng-
Wild 
Aspar
agus 
San-
Shata
vari 
Sarsapopg
enin; 
Sitosterol; 
Asparagam
ine A; 
ȕsitosterol; 
Diosenin;S
arasapogen
in; Rutin 
Leaf, 
Tube
r 
Eenip
u 
Thatpa
m 
Eenipu Nutritiv
e; 
Demulc
ent; 
Galacta
gogue; 
Aphrodi
siac; 
Anti- 
Spasmo
dic 
3
4 
Chukku Zingib
er 
officin
alae 
Zingib
eracea
e 
Hin-
sonth 
San=
nagar
am 
Eng=
dried 
ginge
r 
Gingerol 
Zingerone 
Shagaol 
Tube
r(dry) 
karpu Veppam  karpu Stimula
nt 
Stomach
ic 
carminat
ive 
 Milagu Piper 
nigrum 
Pipera
ceae 
Hin-
kali 
mirch 
San-
maric
ha 
Eng-
black 
peppe
r 
Piperine 
Pinene 
Alkaloids 
flavanoids 
Lignans 
sabinene 
seed Kaipu.
karpu 
veppam karpu Acrid 
Carmina
tive 
Antiperi
odic 
Rubefac
ient 
Stimula
nt 
Resolve
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nt 
Antivath
a 
antidote 
 Thippill
i 
Piper 
longu
m 
Pipera
ceae 
Eng-
long 
peppe
r 
Tel-
pippil
u 
San-
pippa
li 
Piperine 
Rutin 
Beta- 
caryophylli
ne 
Piperyline 
piperoleine
s 
Seed 
Thip
pilli 
rice 
Inippu 
 
tatpam inippu Stimula
nt 
carminat
ive 
3
5 
Koogai 
Neer 
Marant
a 
arundi
naceae 
linn 
Marant
aceae 
Hin-
tikhar 
Eng- 
east 
India
n 
arrow 
root 
 
 Rhiz
ome 
Enipp
u 
Tatpam Enippu Refriger
ent, 
demulce
nt, 
nutrient  
3
6 
Nilapan
aikizhan
gu 
Curcul
igo 
orchioi
des 
Hin-
musal
ikano 
Eng-
black 
musal
e 
San-
musal
e 
Curculigos
ide A.B 
and C 
Curculigin
e A and D 
Root 
and 
tuber 
inippu tatpam inippu Tonic 
Dieureti
c 
Astringe
nt 
Carmina
tive 
emolient 
3
7 
Mutthak
asu 
Cyperu
s 
Rotund
us 
Linn 
Hin-
Muth
a 
Eng-
Nut 
Grass 
San-
Must
Cineol; 
Copaena; 
Cyperen I 
& II; 
Isopatchou
enone; 
Rotundone 
Mustakane
; 
Kobusone; 
Tube
rs 
Kaipp
u 
seetham  Astringe
nt; 
Stimula
nt;Tonic
; 
Diuretic
; 
Diaphor
etic; 
Demulc
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a Sugenol;ȕs
itosterd; 
Copadiene 
ent; 
Vermifu
ge; 
Emmen
agegue 
3
8 
Sitrattai  Alpini
a 
Galang
a Linn 
Hin- 
Eng- 
Galan
gal 
the 
Lasse
r 
San- 
Rasna 
Galangin; 
Kaempferi
de; Diaryl- 
Heptanoids 
Root Karpp
u 
Vetpam Karppu Expecto
rant, 
febrifug
e, 
Stomach
ic. 
 
SULPHUR: 
 Sulfur is a chemical element with symbol of “S”and atomic number “16”. 
 It is an abundant multivalentnon- metal.   
 Sulfur is the third most abundant mineral in the body;about half concentrated in our 
muscles, skin and bones and is essential for life. 
 Sulfur is the sixth most abundant macro- mineral in human breast milk  
 It is widely distributed in close proximity to hot springs and volcanoes. 
 Sulfur is an essential nutrient and therefore cannot be synthesized by the human body 
and instead must be obtained from the diet. 
 Sulfur is not present as an isolated element in the body, the primary placement of 
sulfur in the human body is in the sulfur-containing amino acids (SSA). 
 Methionine, cysteine and taurine are the sulfur containing amino acids. 
 The human body composed of 0.2 – 0.3% sulfur. 
 Generally, proteins contain about1% sulfur by weigh.  
PHYSICAL PROPERTIES: 
Color: Pale yellow, non- metallic 
Phase: Solid 
Crystalline structure & forms: Rhombic, Amorphous and Prismatic 
Odor: Odorless  
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Taste: Tasteless 
Solubility:Insoluble in water 
Boiling point: 444.6oC 
Conductivity: A poor conductor of heat and electricity 
Viscosity: Upon melting, sulfur is converted into a mobile  
Yellow liquid 
 
CHEMICAL PROPERTIES: 
Chemical formula: S 
Compounds: Hydrogen sulfide, Sodium sulfide 
Oxidation: Sulfur dioxide, sulfur trioxide 
Reactivity: It is chemically reactive especially upon heating,  
Sulfur reacts with metals 
BIOCHEMICAL FUNCTION: 
x Cellular energy production & metabolism 
x Maintaining blood glucose levels 
x Protects nerve tissue – Synthesizes neurotransmitters, improves memory 
x Antioxidant protection – Scavenges or neutralizes free radicals and  
 Recycles oxidized antioxidants 
x Blood flow – Produces both blood clotting factors as well 
as Anticoagulants. 
x Joint health– Production of glycosaminoglycan’s (GAGS), 
                                            Chondroitin sulfateand hyaluronic acid 
x Detoxification – By means of conjugation and chelation  
x Digestion – Production of hydrochloric acid 
x Supports healthy lipoprotein balance – Cholesterol, LDL and HDL 
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x Proper immune response– Enhancing proliferation of lymphocytes,  
CytotoxicT cell and NK cells. 
x Lungs – Protects against mucous formation in lungs 
x Eyes – Decreases cataract development. 
x Formation of Skin, Hair and Nails. 
x Regulation of DNA  replication and transcription.  
DIETARY REQUIREMENTS AND SOURCES:  
There is no specific dietary requirement for sulfur. Adequate intake of sulfur 
containing essential amino acid methionine will meet the body needs. Food proteins rich in 
methionine and cysteine are the sources of sulfur.[28] 
METABOLISM OF SULFUR:  
x Sulfur is metabolized by all organisms, from bacteria plants and animals. 
x Sulfur is reduced or oxidized by organisms in a variety of forms. 
x The element is present in proteins, nucleic acid, sulfates, esters of polysaccharides, 
steroids, phenols, and sulfur-containing co-enzymes.  
ROLE OF SULFUR IN RHEUMATIOD ARTHRITIS 
 Sulfasalazine is a drug used in the treatment of rheumatoid arthritis and some other 
autoimmune condition. 
 It helps with pain and swelling and also slows the progression of arthritis over time. 
 Sulfasalazine is also known as a disease modifying anti rheumatic drug (DMARDs), 
because it not only decreases the pain and swelling of arthritis, but also prevent 
damage to joint. 
 It may reduce the risk of long term loss of function. 
PROCEDURE : 
PREPARATION:: 
                1.The raw drugs are collected and dried in sunshade,it is then pulvarised to 
make a fine powder(chooranam). 
              2.Sugar syrup is made with Thaneervittan kilanghu charu(Asparagus 
racemosus). 
  
       
        
 
          ELAM 
   GANDHAGAM     KOOKAINEER 
POOLANKILANGU 
         VETTIVER 
   SATHIPATHIRI 
     SANDANAM KARUNSEERAGA        KIRAMBU 
SITHIRAMOOLAM    MUNTHIRIGAI       SEERAGAM 
GANDHAGA RASAYANAM(INT) 
         
                                                  
 
       
         
       VASAMBU         SATHIKAI 
VAIVIDANGAM 
KORAIKILANGU 
KUNGUMAPOO 
         OMAM 
      AMUKKRA          MILAGU THANEERVITAN 
   POONAIKALI         CHUKKU 
        ARATHAI 
    
                
    SADAMANJIL 
      THAKKOL 
          MALLI       SEERAGAM 
           GANDHAGA RASAYANAM(INT) 
PARANGIPATTAI 
    SATHIPTHRII 
NILAPANAIKILAN
          NELLI      VILAMICHUVER 
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              3.Sulphur purified with cow’s ghee and the chooranam is added to sugar 
syrup and stirred well. 
              4.The mixture is allowed to cool and then the honey is added.    
              5.The above prepared medicine is preserved in a pot and kept in Nerpudam 
for 10 days. 
EXTERNAL MEDICINE : 
 NAVANATHASITTHA THAILAM 
  Reference : Theren thaila varga surukkam 
  (Pg.No:133) 
  Dose   : 25ml for external use 
INGREDIENT: 
s.no Tamil name Botanical 
name& 
family 
 
Quantity 
1 Thazhuthazhai Clerodendrum 
phlomidis linn 
Verbinaeceae 
700gram 
2 Erukku Calotropis 
gigantea linn 
Asclepiadaceae 
700gram 
3 Umattai Datura metal 
Solanaceae 
700gram 
4 Amanakku Ricinus 
communis 
Euphorbiaceae 
700gram 
5 Kandangkathiri Solanum 
surattense burm 
Solanaceae 
700gram 
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6 Karisalai Eclipta prostrate 
linn 
Asteraceae 
700gram 
7 Nochi Vitex nirgundo 
linn 
Verbinaceae 
700gramI 
8 Chukka Zingiber 
officinale 
Scitaminae 
17.5gram 
9 Thamarai 
valaiyam 
Nelumbo 
nucifera grertn 
Nelumbonaceae 
17.5gram 
 
10 Kadugu Brassica juncea 
hook 
Crucuferae 
17.5gram 
11 Kostam Costus 
speciosus 
Zingiberaceae 
17.5gram 
12 Agil Katta Aqualaria 
agallocha 
Thymaliaceae 
17.5gram 
13 Vasambhu Acorus calamus 
linn 
Araceae 
17.5gram 
14 Vellai poondu Allium sativum 
linn 
Liliaceae 
17.5gram 
15 Thippilli Piper longum 
linn 
Piperaceae 
17.5gram 
16 Ati Mathuram Glycyrrhiza 
glabra linn 
Fabaceae 
17.5gram 
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17 Vai vilangam Embellica ribes 
burm 
Myrsinaceae 
17.5gram 
18 Adathoda Justicia 
beddomei 
bennet 
Acanthaceae 
700gram 
19 Shadurakalli Euphorbia 
antiqurum linn 
 
700gram 
20 Koraikilanghu Cyperus 
rotundus 
 
17.5gram 
21 Arattai Alpinia galangal 
linn 
Zingiberaceae 
17.5gram 
22  Sandanam Santalum album 
linn 
Santalaeceae 
17.5gram 
23 Thiripalai Three 
myrobalans 
 
17.5gram 
24 Induppu Rock salt 17.5gram 
 
25 
Ellu nei 
Amanakkunei 
Veppennai 
 
Sesamam 
indicum 
Ricinus 
communis 
Azadirecta 
indica 
1 padi 
each 
(1.8 litre) 
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DESCRIPTION OF EXTERNAL MEDICINE: 
s.
n
o 
Tamil 
name 
Botanic
al 
name& 
family 
Verna
cular 
name 
Chemic
al 
compos
ition 
Part
s 
used 
Suvai
i 
Tan
mai 
Piri
vu 
actions 
1 Thazhuth
azhai 
Cleroden
drum 
phlomidis 
linn 
Verbinae
ceae 
Hin-
tekar 
Eng-
wind 
killer 
San- 
agnima
ntha 
Apigenin
, luteolin, 
betulin, 
premnen
ol, 
caryophe
llen, 
Root 
bark, 
leaf 
Kaipp
u, 
thuvar
ppu 
Vepp
am 
Kar
ppu 
Alterativ
e, 
astringe
nt 
2 Erukku Calotropi
s 
gigantea 
linn 
Asclepiad
aceae 
Hin-
madara 
Eng-
madar 
San-
arka 
Laurane, 
b-
amyrin, 
calactin, 
calotoxin
, 
gigantin, 
taraxaste
rol 
Root 
bark, 
flowe
r, 
leaf, 
seed 
Kaipp
u, 
karam
, 
madh
uram 
Vepp
am 
Kar
ppu 
Anthelm
entic, 
alternati
ve, 
laxative, 
stimulan
t 
3 Umattai Datura 
metal 
Solanace
ae 
Hin-
sada 
dhatura 
Eng- 
thorn 
apple 
San- 
dhattura 
Daturadi
ol, 
hyosine, 
sitosterol
, 
datumeli
n, 
daturilin, 
norhysin
e, 
factusine 
Root, 
flowe
r, 
leaf, 
fruit/ 
seed 
Kaipp
u 
Vepp
am 
Kar
ppu 
Emetic, 
anti 
spasmod
ic, 
anodyne
, 
narcotic 
4 Amanak
ku 
Ricinus 
communi
s 
Euphorbi
aceae 
Hin-
erand 
Eng- 
castor 
San- 
eranda 
Ricinine, 
lupeol, 
lipids, 
strearic 
acid, 
hydrocya
nic & 
uric 
acids, 
tocopher
ols 
Root, 
leaf, 
seed 
oil 
Kaipp
u 
Vepp
am 
Kar
ppu 
Galactag
ogue, 
anti 
vata, 
laxative, 
emollien
t 
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5 Kandang
kathiri 
Solanum 
surattense 
burm 
Solanace
ae 
Hin-
choti 
kateri 
Eng-
yellow 
berried 
nightsh
ade 
San- 
kantaka
ri 
Diosgeni
n, 
solasodin
e, 
tomatidie
nol, 
solam 
carpine 
Whol
e 
plant 
Karpp
u 
Vepp
am 
Kar
ppu 
Expecto
rant, 
diuretic, 
carminat
ive 
6 Karisalai Eclipta 
prostrate 
linn 
Asteracea
e 
Hin- 
bhangra 
Eng- 
trailing 
eclipta 
San- 
bhrngar
aja 
Ecliptal, 
stigmaste
rol, 
heptacos
anol, 
hentriaca
ntol 
Whol
e 
plant 
Kaipp
u 
Vepp
am 
Kai
ppu 
Alterativ
e, emet, 
purgativ
e, hepic 
tonic, 
cholago
gue 
7 Nochi Vitex 
nirgundo 
linn 
Verbinac
eae 
Hin-
samhal
u 
Eng-
five 
leaved 
chaste 
San- 
nirgund
i 
Phenol, 
dulcitol, 
vitricine, 
b-
sitosterol
, 
camphen
e, 
casticine, 
orientin 
Leaf, 
root, 
seed 
Kaipp
u, 
thuvar
ppu, 
karpp
u 
Vepp
am 
Kar
ppu 
Alterativ
e, 
vermifu
ge, 
expector
ant, 
astringe
nt, 
refrigera
nt 
8 Chukka Zingiber 
officinale 
Scitamina
e 
Hin-
sonth 
Eng-
ginger 
San-
sunthi 
Citral, 
paradol, 
zingibero
l, 
zingeron
e 
,geraniol, 
camphen
e 
Rhiz
ome 
Karpp
u 
Vepp
am 
Kar
ppu 
Stimula
nt, 
stomach
ic, 
carminat
ive 
9 Thamarai 
valaiyam 
Nelumbo 
nucifera 
grertn 
Nelumbo
naceae 
Hin- 
kamal 
Eng- 
lotus 
San- 
Robinin, 
nuciferin
, 
asmilobi
ne, 
lirinidine
, 
Whol
e 
plant 
Enipp
u, 
thuvar
ppu 
Seeta
m 
Eni
ppu 
Cooling, 
astringe
nt, 
expector
ant, 
sedative, 
demulce
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kamal neferine, 
armepavi
ne, iso 
liensinin
e 
nt, tonic, 
nutritive 
10 Kadugu Brassica 
juncea 
hook 
Crucufera
e 
Hin-
badshah 
rai 
Eng-
,Indian 
mustard 
San- 
rajika 
Sinigrin, 
sinapine, 
gluconap
in 
Seed 
seed 
oil 
Kara
m 
Vepp
am 
Kar
ppu 
Emetic, 
stimulan
t, 
vesicant, 
digestiv
e, 
diuretic 
11 Kostam Costus 
speciosus 
Zingibera
ceae 
Hin- 
kebu 
Eng-
costus 
root 
San- 
kebuka 
Saponins
- 
A,B,C,D  
Tigogeni
n, 
diosgeni
n, 
costusosi
des 
Rhiz
ome 
Kaipp
u, viru 
virupp
u 
Vepp
am 
Kar
ppu 
Stomach
ic, 
expector
ant, 
stimulan
t, 
diaphore
tic 
12 Agil 
Katta 
Aqualaria 
agallocha 
Thymalia
ceae 
Hin- 
agar 
Eng- 
agar 
wood, 
san- 
agaru 
Agarospi
rol, 
aquilloch
in, 
kusunol, 
lignin, 
jinkohol, 
pentosan
s 
Arom
atic 
resin
ous 
wood
, oil 
Karpp
u, 
kaipp
u, 
enipp
u 
Vepp
am 
Eni
ppu 
Stimula
nt, de 
obstruen
t, 
cholago
gue 
13 Vasambh
u 
Acorus 
calamus 
linn 
Araceae 
Hin- 
vacha 
Eng- 
sweet 
flag 
San- 
vaca 
Acolamo
ne, 
acorone, 
azulene, 
eugenol, 
telekin, 
acoric 
acid, 
calamen
diol, 
cadalene 
Rhiz
ome 
Karpp
u 
Vepp
am 
Kar
ppu 
Stimula
nt, 
stomach
ic, anti-
periodic, 
emetic, 
carminat
ive, 
germicid
e 
14 Vellai 
poondu 
Allium 
sativum 
linn 
Hin- 
lahasun 
Eng- 
Allin, 
arabinos
e, 
galactose
Bulb, 
oil 
Karpp
u 
Vepp
am 
Kar
ppu 
Carmina
tive, 
stomach
ic, tonic, 
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Liliaceae garlic 
San- 
rasona 
, amino 
acids, 
allinase, 
methiani
ne, 
asparagic 
acid, 
ajoena 
alterativ
e, 
anthelmi
ntic, 
expector
ant 
15 Thippilli Piper 
longum 
linn 
Piperacea
e 
Hin- 
pipala 
Eng- 
long 
pepper 
San- 
pippali 
Caryoph
yllene, 
piperine, 
piplartin
e, 
pipercide
, 
sesamin, 
piper 
nonaline 
Fruit, 
root 
Enipp
u 
Vepp
am 
Eni
ppu 
Stimula
nt, 
carminat
ive 
16 Ati 
Mathura
m 
Glycyrrhi
za glabra 
linn 
Fabaceae 
Hin- 
mulethi 
Eng- 
liquoric
e 
San- 
yasti 
madhu 
Glabroli
de, 
glabrine, 
glycyrrhi
zin, 
liquirtin, 
iso 
liquirtin 
Root Enipp
u 
Seeta
m 
Eni
ppu 
Emollie
nt, 
demulce
nt, tonic, 
laxative, 
mild- 
expector
ant 
17 Vai 
vilangam 
Embellic
a ribes 
burm 
Myrsinac
eae 
Hin-vai 
vidang 
Eng-
emebeli
a 
San- 
vidanga 
Embelin, 
christem
bine, 
quercitol, 
homorap
anone 
Fruits
, root 
Kaipp
u 
Vepp
am 
Kar
ppu 
Anthelm
intic, 
carminat
ive, 
stomach
ic, 
stimulan
t 
18 Adathod
a 
Justicia 
beddomei 
bennet 
Acanthac
eae 
Hin- 
arusa 
Eng-
malabar 
nut 
San- 
vasaka 
Adathodi
c acid, 
kaemfero
l, 
carotene, 
vasicinol
, 
anisotine
, 
adathodi
ne 
Leaf, 
root, 
bark, 
flowe
r 
Kaipp
u 
Vepp
am 
Kar
ppu 
Anti- 
spaamod
ic, 
expector
ant, 
germicid
e, 
diuretic 
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1
9 
Shadurak
alli 
Euphorbi
a 
antiquru
m linn 
 
Hin-
sehund 
Eng-
quadran
gular 
spurge 
San- 
maha 
snuhi 
 
 Late
x, 
root 
bark 
karppu vepp
am 
karp
pu 
 
2
0 
Koraikila
nghu 
Cyperus 
rotundus 
 
Hin 
mutha 
Eng- nut 
grass, 
san- 
musta 
Cineol, 
copaene, 
mustako
ne, 
kobuson
e, 
sugenol, 
copadien
e 
Tub
ers 
Kaipp
u 
Seeta
m 
Kaip
pu 
Astringe
nt, 
stimulan
t, 
diuretic, 
demulce
nt, 
vermifu
ge 
2
1 
Arattai Alpinia 
galangal 
linn 
Zingibera
ceae 
Eng- 
galangal 
the 
lesser 
San- 
rasna 
Galagin, 
kaempfe
ride, 
diaryl- 
heptanoi
ds 
Roo
t 
Kaarp
pu 
Vepp
am 
Karp
pu 
Expecto
rant, 
febrifug
e, 
stomach
ic 
2
2  
Sandana
m 
Santalum 
album 
linn 
Santalaec
eae 
Hin-
chandan 
Eng-
sandal 
wood 
San- 
chandan
a 
Santano
ne, tere 
santalic 
acid, b-
santene 
& 
santalen
es, nor- 
tricycle 
ekasanta
la 
Oil, 
who
le 
plan
t 
Kaipp
u, siru 
thuvar
ppu 
Tatpa
m, 
vepp
am 
Enip
pu 
karp
pu 
Alterativ
e, 
diuretic, 
diaphore
tic, 
stimulan
t, dis 
infectant
, 
astringe
nt, 
cooling 
2
3 
Thiripalai Three 
myrobala
ns 
San-
thriphala 
 
Gallic 
acud 
Chebula
gic acid 
Chebulin
ic acid 
fruit thuvar
ppu 
vepp
am 
karp
pu 
astringe
nt 
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2
4 
Induppu Rock salt Cynthav
am 
chindoor
am 
Cream 
of tartar 
salt    Laxative 
Purgativ
e 
Carmina
tive  
Diuretic 
Stomach
ic 
 
PROCEDURE: 
y Roots are collected and dried in sun shade and it pulvarised to make a powder  then decoction 
is prepared with this powder. 
y Oil  are added to the above decoction. 
y Raw drugs are collected and dried in sun shade and pulvarised to powder form and made into 
Karkam. 
y Karkam is added to the above preparation and boiled in low flame to required consistency and 
collected in a pot sealed with mud pasted cloth(seelai) is kept in nerpudam for 9 
days.(THERAN THAILA VARGA SURUKAM)  
                                     
 
 
 
 
 
 
 
 
`   
       
          
      UMATHAI     THALUTHALAI 
 MUSUMUSUKAI 
THAMARAIVALAI        KADUGU 
          NOCHI 
   SATHURAKALLI 
    AMMANAKKU          KARISALAI       ADATHODAI 
         ELLU NEI 
         CHUKKU 
NAVANATHASITTHA TAILAM(EXT) 
  
 
 AMMANAKU NEI        AGIRKATTAI 
ATHIMATHURAM    VAIVIDANGAM 
       ERRUKU 
      VEPPENNAI 
NAVANATHASITTHA 
TAILAM(EXT) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS & 
OBSERVATIONS 
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RESULTS AND OBSERVATION 
Results and observation are tabulated under the following headings, 
1. Age Distribution 
2. Sex Distribution 
3. Gunam 
4.  Body constitution 
5. Paruva Kaalam 
6. Nilam 
7. Diet 
8. Occupational Distribution  
9. Socio economic status 
10. Duration of illness 
11. Onset of Symptoms 
a. Derangement in Vatham 
b. Derangement in Pitham 
c. Derangement in Kabam 
12. Gnanenthriyam 
13. Kanmenthiriyam 
14. Udalthathukkal 
15. Envagai thervugal 
A) Naadi 
B) Neikuri 
16. Clinical Features 
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17. Deformities 
18. Involvement of Joints 
19. Results 
1. AGE DISTRIBUTION: 
AGE [YEAR] NUMBER OF 
CASES 
PERCENTAGE 
18-20 1 2.5% 
21-30 3 7.5% 
31-40 15 32.5% 
41-50 12 30% 
51-60 11 27.5% 
Total 40 100% 
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OBSERVATION: 
             The percentage of the age group18-20 was 2.5%, 21-30 was 7.5%, 31-40 was 
32.5%, 41-50 was 30% , 51-60 was 27.5%. 
 
GENDER: 
 
 
0
5
10
15
20
25
30
35
18-20 21-30 31-40 41-50 51-60
Series
1
GENDER NUMBER OF CASES PERCENTAGE 
Male 1 2.5% 
Female 39 97.5% 
Total 40 100% 
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2. SEX DISTRIBUTION: 
 
OBSERVATION: 
      Among the 40 patients selected 97.5% were females and 2.5% were males. 
3. GUNAM: 
GUNAM NUMBER OF CASES PERCENTAGE 
Sathuva gunam - - 
Rasatha gunam 38 95% 
Thamo gunam 2 5% 
Total 40 100% 
 
 
2.50%
97.50%
GENDER
Male
Female
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OBSERVATION: 
                Among the 40 cases, 38 cases were found to possess rasatha gunam and 2 
cases were found to possess thamo gunam. 
\4. BODY CONSTITUTION: 
CONSTITUTION OF 
THE BODY 
NUMBER OF 
CASES 
PERCENTAGE 
Vatha thegi 3 7.5% 
Pittha thegi - - 
Kabha thegi - - 
Thontha thegi 37 92.5% 
Total 40 100% 
 
 
 
95.00%
5.00%
GUNAM
Sathuva gunam
Rasatha gunam
Thamo gunam
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OBSERVATION: 
In the study 3 cases belongs to vadha thegi  and 37 cases belongs to thontha 
thegi.  
5.PARUVAKAALAM: 
PARUVAKAALAM NUMBER OF CASES PERCENTAGE 
Kaarkaalam 11  27.5% 
Koothirkaalam 9 22.5% 
Munpanikalam 4 10% 
Pinpanikaalam 5 12.5% 
Ilavenilkaalam 3 7.5% 
Mudhuvenilkaalam 8 20% 
Total 40 100% 
 
NUM OF CASE
VADHA DEGI
PITHA DEGI
KABA DEGI
THONTHA DEGI
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OBSERVATION: 
Among the 40 cases, 27.5% of cases were admitted to the trail in 
kaarkaalam,22.5% of cases  in koothirkalam and 10% cases in munpanikalam,12.5% 
in pinpani kalam 7.5% cases in ilavenilkalam,20% in mudhuvenilkaalam. 
6.NILAM: 
NILAM NUMBER OF CASES PERCENTAGE 
Kurinji - - 
Mullai - - 
Marudham 2 5% 
Neithal 38 95% 
Palai - - 
Total 40 100% 
 
0
0.05
0.1
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OBSERVATION: 
Among  the  40  cases,  5%  cases  were  from  marutha  nilam  and  the  remaining  
95% cases from neithal nilam.        
7.DIET: 
DIET NUMBER OF CASES PERCENTAGE 
Vegetarian 5 12.5% 
Non vegetarian 35 87.5% 
Total  40 100% 
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OBSERVATION: 
          Among the 40 cases, 87.5% were non vegetarian and 12.5% were 
vegetarian. 
 
8.OCCUPATIONAL DISTRIBUTION: 
OCCUPATION NUMBER OF CASES PERCENTAGE 
House wife 25 62.5% 
Teacher 1 2.5% 
Housemaid  4 10% 
Driver  1 2.5% 
Clerical 4 10% 
Farmer 5 12.5% 
Total 40 100% 
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OBSERVATION: 
          Among the 40 cases, 62.5% were housewives, 12.5% were farmers, 10% were 
clericals and housemaids, 2.5% were teachers and drivers. 
9. SOCIO-ECONOMIC STATUS: 
SOCIO ECONOMIC 
STATUS 
NUMBER OF CASES PERCENTAGE 
Poor 11 27.5% 
Middle class 25 62.5% 
Upper middle class 4 10% 
Total  40 100% 
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OBSERVATION: 
            The incidence of the disease was found in 62.5% in middle class, 27.5% in 
poor and 10% in upper middle class. 
10.DURATION OF ILLNESS: 
DURATION OF 
ILLNESS 
NUMBER OF CASES PERCENTAGE 
3 months – 6 months 7 17.5% 
6 months- 1 year 8 20% 
1year -2yrs 11 27.5% 
2-5 years 10 25% 
5-10 years 3 7.5% 
more than 10 years 1 2.5% 
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OBSERVATION: 
         Among the 40 cases, the duration of the illness at the time of study 27.5% were 
1yr-2yrs, 25% were 2-5 yrs, 20% were 6months- 1yr, 17.5% were 3months- 6 
months, 7.5% were 5-10 yrs, 2.5% were more than 10 yrs. 
 
11. ONSET OF DISEASE: 
 
 
OBSERVATION: 
            All the 40 cases are of gradual onset. 
 
NUMBER OF CASES
Sudden
Gradual
Total
MODE OF ONSET NUMBER OF CASES PERCENTAGE 
Sudden - - 
Gradual 40 100% 
Total 40 100% 
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12.DISTURBANCES IN VATHAM: 
VATHAM NUMBER OF CASES PERCENTAGE 
Praanan 23 57.5% 
Abaanan 3 7.5% 
Samaanan 40 100% 
Viyaanan 40 100% 
Udhaanan 24 60% 
Naagan 12 30% 
Koorman 12 30% 
Kirukaran 12 30% 
Dhevathathan 31 77.5% 
Dhananjeyan - - 
 
OBSERVATION: 
               Samaanan were affected in 100% of cases, dhevathathan was affected in 
77.5% cases, praanan, udhaanan were affected in 60% of cases, naagan, koorman, 
kirukaran, were affected in 30% of cases. Abaanan was affected in 10% of cases. 
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13.DISTURBANCES IN PITTAM: 
PITHAM NUMBER OF CASES PERCENTAGE 
Analam 15 37.5% 
Ranjakam 13 32.5% 
Saathagam 40 100% 
Alosagam 12 30% 
Total 40 100% 
   
  
 
OBSERVATION: 
         Among  the  40  cases,  saathagam  was  affected  in  100%cases.  Analam  was  
affected in 37.5% of cases, ranjagam was affected in 32.5% cases, alosagam was 
affected in 30% cases, prasagam was affected in 2.5% cases. 
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14.DISTURBANCES IN KABAM: 
KABAM NUMBER OF CASES PERCENTAGE 
Avalambakam 24 60% 
Kilethagam 15 37.5% 
Pothagam 2 5% 
Tharpagam 14 35% 
Santhigam 40 100% 
 
OBSERVATION: 
           Among  the  40  cases,  santhigam  was  affected  in  40  cases,  avalambagam  was  
affected in 60% cases, kilethagam was affected in 37.5% cases, tharpagam was 
affected in 35% cases, pothagam was affected in 5% cases.                                
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15.DISTURBANCES IN GNANENTHIRIYAM: 
GNANENTHIRIYAM NUMBER OF CASES PERCENTAGE 
Mei 40 100% 
Vai 2 5% 
Kan - - 
Mooku - - 
Sevi - - 
 
OBSERVATION: 
Among the 40 cases all mei was affected in 100%cases, kan was affected in 30% 
cases due to age factor and vai was affected in 5% cases.  
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16.KANMENTHIRIYAM INVOLVEMENT:  
KANMENTHIRIYAM NUMBER OF CASES PERCENTAGE 
Kai 40 100% 
Kaal 40 100% 
Vai - - 
Karuvaai - - 
Eruvaai 4 10% 
 
 
 
OBSERVATION: 
         Among the 40 cases, kai kaal are affected in all 100% cases due to pain, 
swelling, restriction of movements,etc. eruvaai was affected in 10% of cases due to 
constipation, vaai was affected in 5% of cases due to stomatitis. 
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17.UDAL THATHUKKAL: 
UDAL THATHUKKAL NUMBER OF CASES PERCENTAGE 
Saaram 40 100% 
Senner 40 100% 
Oon 40 100% 
Kozhuppu 40 100% 
Enbu 40 100% 
Moolai 40 100% 
Sukkilam / suronitham - - 
 
 
OBSERVATION: 
             Saaram, seneer, oon, kozhuppu, enbu, moolai were affected in all the 40 
cases. 
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18.ENVAGAI THERVUGAL: 
ENVAGAI 
THERVUGAL NUMBER OF CASES PERCENTAGE: 
Naadi 40 100% 
Naa 14 35% 
Niram 1 2.5% 
Mozhi - - 
Vizhi 18 45% 
Sparisham 27 67.5% 
Malam 4 10% 
Mootiram - - 
 
  OBSERVATION: 
       In all the cases, examination of naadi, naadi revealed thontham of vatham. 
Sparisam was affected in 67.5% cases due to warmth felt in the affected joints. Vizhi 
was affected in 45% cases , naa was affected in 35% of cases, and mala was affected 
in 10% cases, niram was affected in 2.5%   . 
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19. NAADI: 
NAADI NUMBER OF CASES PERCENTAGE 
Vathapitham 30 75% 
Pitha vatham 10 25% 
Total 40 100% 
     
 
 
OBSERVATION: 
              Among the 40 cases, 75% of the cases were revealed vathapitha naadi, 25% 
of the cases were revealed pithavatha naadi. 
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20. NEIKKURI: 
SPREADING 
PATTERNS NUMBER OF CASES PERCENTAGE 
Vathaneer 31 77.5% 
Pithaneer 2 5% 
Kabaneer 7 17.5% 
total   40 100% 
   
 
 
OBSERVATION: 
        Among the 40 cases, 77.5% of the cases showed vathaneer, 17.5% of the case 
showed kabaneer, 5% of the cases showed pithaneer. 
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21.CLINICAL SYMPTOMS [BEFORE & AFTER] : 
 
S.N
O 
CLINICAL 
FEATURE 
BEFORE TREATMENT AFTER TREATMENT 
SUBJECT
S  
PERCENTA
GE 
SUBJECT
S 
PERCENTA
GE 
1 MORNING 
STIFFNESS 
20 100% 3 15% 
2 PAIN AND 
SWELLING 
OF JOINTS 
20 100% 4 20% 
3 ARTHRITIS 
OF 3orMORE 
JOINTS 
12  60% 4 20% 
4 SYMMETRIC
AL 
INVOLVEME
NT 
10 50% 3 15% 
5 RESTRICTION 
OF 
MOVEMENTS 
20 100% 2 10% 
6 LOW GRADE 
FEVER 
15 75% 1 5% 
 
                              IMPROVEMENT FOR GROUP – I SUBJECTS 
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IMPROVEMENT  FOR  GROUP – II SUBJECTS 
S.N
O 
CLINICAL 
FEATURE 
BEFORE  TREATMENT AFTER  TREATMENT 
SUBJECT
S 
PERCENTA
GE 
SUBJECT
S 
PERCENTA
GE 
1 MORNING 
STIFFNESS 
20 100% 4 20% 
2 PAIN AND 
SWELLING 
OF JOINTS 
20 100% 4 20% 
3 ARTHRITIS 
OF MORE 
THAN 3 
JOINTS 
13 65% 3 15% 
4 SYMMETRIC
AL 
INVOLVEME
NT 
10 50% 2 10% 
5 RESTRICTION 
OF 
MOVEMENT 
20 100% 3 15% 
6  LOW GRADE 
FEVER 
12 60% 1 5% 
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OBSERVATION: 
                  Pain, swelling of joints, morning stiffness, tenderness, restricted 
movements and warmth were found in all 40 cases before treatment. 
After treatment there was a considerable reduction in all symptoms particularly in 
pain, morning stiffness, swelling of joints, tenderness, restricted movements and 
warmth. 
After treatment there was a complete relief in the symptoms like low grade fever, 
sleeplessness and loss of appetite. 
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22.DEFORMITY: 
DEFORMITY NUMBER OF CASES PERCENTAGE 
Spindle shaped fingers 7 25% 
Swan neck 3 7.5% 
Z shaped  - - 
Ulnar deviation of hand 5 12.5% 
Hallus valgus 3 7.5% 
 
 
OBSERVATION: 
            Among the 40 cases, 25%cases had spindle shaped fingers, 12.5% cases had 
ulnar deviation of hand, 7.5% cases had hallus valgus and 7.5% cases had swan neck 
deformity. 
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23.INVOLVEMENT OF JOINTS: 
JOINTS INVOLVED NUMBER OF CASES PERCENTAGE 
Proximal inter phalangeal 
joint of hand 
35 87.5% 
Metacarpo phalangeal 
joint 
35 87.5% 
Wrist joint 30 75% 
Elbow joint 13 32.5% 
shoulder joint 10 25% 
Cervical spine 26 65% 
Hip joint 10 25% 
Knee joint 40 100% 
Ankle joint 35 87.5% 
Meta tarso phalangeal 
joint 
10 25% 
 
OBSERVATION: 
            Among the 40 cases, 100% had knee joint, 87.5% cases had proximal 
interphalangeal joint, ankle joint and metacarpo phalangeal joint, 75% had wrist joint, 
65% had cervical spine, 32% had elbows, 25% had hip joints, shoulder joints, and 
metatarso phalangeal joint. 
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OVERALL RESULTS: 
       RESULTS NO OF CASES    PERCENTAGE 
GOOD                32                  80% 
MODERATE                05                  12.5% 
MILD                03                   7.5% 
NO IMPROVEMENT                 ---                   ------ 
 
 
 
OBSERVATION: 
        Among  40  patients  80%  of  cases  shows  good  results  ,  12.5%  of  cases  shows  
moderate results & 7.5% of cases shows mild results. 
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HAEMOTOLOGICAL INVESTIGATIONS OF GROUP – I SUBJECTS 
SI. No OP. 
NO 
NAME AGE/ 
SEX 
Hb (gm) TC (cu.mm) DC ESR Bl sugar 
N L E ½ 
hr 
1/2
hr 
1hr 1hr      P.P 
BT AT BT AT B
T 
AT B
T 
AT B
T 
AT B
T 
AT BT AT BT AT 
1 1512 Saratha 51/f 13.3 12.8 5900 6500 63 71 27 22 4 6 23 20 46 46 131 128 
2 1395 Thatch
ayini 
58/f 12.1 12.5 5300 6352 75 73 20 24 1 3 18 13 38 39 101 110 
3 3260 Uma 32/f 10.2 11.7 9600 10200 77 73 22 19 1 8 40 26 90 55 122 91 
4 3259 Raman 54/m 12.3 13 7500 6890 62 66 31.
3 
27 3.1 7 20 18 40 37 110 98 
5 6446 Selvi 57/f 12.1 12.5 9800 8700 70 69 23 25 7 6 34 28 70 60 115 110 
6 7048 Stella 33/f 9.9 10.6 7010 6700 57 64 32.
1 
31 3.8 5 33 29 66 58 100 91 
7 7050 Santhi 33/f 12 12.8 7000 6864 60 65 35 27 5 8 19 11 36 27 106 98 
8 3467 Theepa 39/f 10.2 11 8900 7420 63 69 31 25 5 6 18 15 56 34 123 106 
9 2099 Uma 
mahesh
wari 
40/f 10.5 12 1321
0 
8460 62.
6 
69 30.
9 
26 1.8 5 18 14 36 30 121 119 
10 9124 Laksh
mi 
25/f 9.6 11.7 1280
0 
7900 88 58 9 40 1 2 25 15 50 32 150 98 
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11 9125 Vijaya 50/f 8.9 10.3 1100
0 
8736 68 73 28 21 4 6 29 21 58 45 141 129 
12 1420 Vedava
lli 
40/f 10 12 1054
0 
8750 64.
9 
72.
4 
27.
7 
21.
9 
7.4 5.2 26 22 52 48 117 104 
13 3430 Porkodi 31/f 10.8 11.4 9570 8210 59.
5 
67.
6 
32.
1 
25.
4 
8.4 7 12 10 24 21 98.
2 
110 
14 4520 Amuth
a 
56/f 10.8 11 6800 7000 64 69 31 27 3 4 19 17 38 35 110 112 
15 4349 Susmit
ha 
20/f  
7.8 
9 5090 6500 53.
5 
60 32.
8 
28.
5 
4.4 6 27 21 54 45 110 98 
16 5290 Kasthur
i 
60/f 11 11.7 8380 5970 65.
1 
52.
3 
25.
5 
36.
5 
3.1 4.2 25 20 50 40 83 91 
17 9454 Rajesh
wari 
49/f 11.7 12.4 1331
0 
10100 52.
8 
71 35.
9 
22.
1 
4 0.9 26 18 52 38 82 93 
18 6384 Kamala
veni 
48/f 14.1 12.6 1170
0 
6100 69 58.
9 
27 32.
3 
4 0.4 10 6 24 15 91 100 
19 9140 Kavitha 29/f 13.8 13 8190 8000 68.
2 
71.
5 
24 22.
5 
2.2 6 12 10 25 21 143 138 
20 9635 suriyak
umari 
59/f 11.2 12 9240 8800 68.
7 
65 23.
7 
25 2.4 8 26 20 55 45 120 115 
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LFT, RFT AND URINE ANALYSIS OF GROUP – I SUBJECT 
 
 
 
S.NO 
 
 
 
OP.NO 
 
 
NAME 
 
 
AGE/ SEX 
                         LIVER FUNCTION TEST 
BEFORE  TREATMENT AFTER TREATMENT 
Serum 
Alkaline 
phosphatase 
SGOT SGPT  
 
Serum Alkaline 
phosphatase 
SGOT SGPT  
 
1 1512 saradha 51/f 99 27 23 93 21 19 
2 1395 Thatchayini 58/f 95 14 10 89 12 13 
3 3260 Uma 32/f 80 20 12 96 18 14 
4 3259 Raman 54/m 83 16.4 15.9 91 20.4 18.6 
5 6446 Selvi 57/f 81 18.1 15.7 98 17.7 16.4 
6 7048 Stella 33/f 106 21 19 100 30 23 
7 7050 Santhi 33/f 76 19.2 12.9 80 20 15 
8 3467 Theepa 39/f 76 19.2 12.9 79 20.7 14.8 
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9 2099 Uma 
maheshwari 
40/f 90 13.8 9.0 94 15.2 11.3 
10 9124 Lakshmi 25/f 94 14.8 18 90 16 20 
11 9125 Vijaya 50/f 84.7 19.1 25 86 24 29 
12 1420 Vedavalli 40/f 102 24 21.8 99.6 25.9 22.6 
13 3430 Porkodi 31/f 99 21 20.1 89 18.3 17.2 
14 4520 Amutha 56/f 96.7 18.3 17.1 101 19.6 18.1 
15 4349 Susmitha 20/f 76 14 14 79 16 16 
16 5290 Kasthuri 60/f 79 17.9 15 83 19 13 
17 9454 Rajeshwari 49/f 42 24.7 16.9 68 26 19 
18 6384 Kamalaveni 48/f 53 30.7 22.2 65 29.6 24.3 
19 9140 Kavitha 29/f 135 20.6 17 110 25.9 25.3 
20 9635 Suriyakumari 59/f 107 18.4 11.2 95 17 12 
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RRENAL FUNCTION TEST 
 
 
S.NO 
 
 
OP.NO 
 
 
NAME 
AGE/ 
SEX 
RENAL FUNCTION TEST 
BEFORE TREATMANT AFTER TREATMANT 
UREA CREATININE UREA CREATININE 
1 1512 Saradha 51/f 17 0.79 21.2 0.64 
2 1395 Thatchayini 58/f 25 0.8 12.5 0.6 
3 3260 Uma 32/f 25 0.9 14 0.8 
4 3259 Raman 54/m 20.2 0.96 26.9 0.75 
5 6446 Selvi 57/f 30 0.81 28 0.54 
6 7048 Stella 33/f 27.9 0.67 31 0.45 
7 7050 Santhi 33/f 34 0.99 29 0.61 
8 3467 Theepa 39/f 14.7 0.69 16 0.47 
9 2099 Uma 
maheshwari 
40/f 22.8 0.54 19.9 0.62  
10 9124 Lakshmi 25/f 21 0.67 23 0.71 
11 9125 Vijaya 50/f 34 0.73 29 0.51 
12 1420 Vedavalli 40/f 17 0.99 19 0.78 
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13 3430 Porkodi 31/f 21 1.01 19 0.91 
14 4520 Amutha 56/f 30 0.96 27.8 0.87 
15 4349 Susmitha 20/f 19 0.80 19.9 0.71 
16 5290 Kasthuri 60/f 18.5 0.87 20 0.73 
17 9454 Rajeshwari 49/f 13.9 0.80 17 0.70 
18 6384 Kamalaveni 48/f 10.2 0.7 18 0.56 
19 9140 Kavitha 29/f 26.7 0.66 23.4 0.66 
20 9635 Suriyakumari 59/f 24.5 0.55 21.2 0.49 
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UREINE ANALYSIS GROUP I 
 
 
S.NO 
 
 
OP.N
O 
NAME AGE/ SEX URINE ANALYSIS 
ALBUMIN SUGAR DEPOSIT 
BT AT BT AT BT AT 
1 1512 Saradha 51/f NIL NIL NIL NIL NIL NIL 
2 1395 Thatchayini 58/f NIL NIL NIL NIL NIL PC 
3 3260 Uma 32/f NIL NIL NIL NIL NIL NIL 
4 3259 Raman 54/m NIL NIL NIL NIL NIL NIL 
5 6446 Selvi 57/f NIL NIL NIL NIL NIL NIL 
6 7048 Stella 33/f NIL NIL NIL NIL PC NIL 
7 7050 Santhi 33/f NIL NIL NIL NIL NIL NIL 
8 3467 Theepa 39/f NIL NIL NIL NIL NIL NIL 
9 2099 Uma maheshwari 40/f NIL NIL NIL NIL NIL PC 
10 9124 Lakshmi 25/f NIL NIL NIL NIL NIL NIL 
11 9125 Vijaya 50/f NIL NIL NIL NIL NIL NIL 
12 1420 Vedavalli 40/f NIL NIL NIL NIL PC NIL 
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13 3430 Porkodi 31/f NIL NIL NIL NIL NIL NIL 
14 4520 Amutha 56/f NIL NIL NIL NIL NIL PC 
15 4349 Susmitha 20/f NIL NIL NIL NIL NIL NIL 
16 5290 Kasthuri 60/f NIL NIL NIL NIL PC NIL 
17 9454 Rajeshwari 49/f NIL NIL NIL NIL NIL NIL 
18 6384 Kamalaveni 48/f NIL NIL NIL NIL NIL PC 
19 9140 Kavitha 29/f NIL NIL NIL NIL NIL NIL 
20 9635 Suriyakumari 59/f NIL NIL NIL NIL PC NIL 
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IMMUNOLOGICAL REPORT 
S.NO OP NO NAME AGE/ 
SEX  
RA FACTOR  ANTI CCP 
BT AT BT AT 
1 1512 Saratha 51/f 90 87 198.79 195.5 
2 1395 Thatchayini 58/f 24 21 28 24 
3 3260 Uma 32/f 149 149.97 31 31.98 
4 3259 Raman 54/m 38.8 36.1 24 21 
5 6446 Selvi 57/f 114 113 20 18.64 
6 7048 Stella 33/f 50.95 50.18 11.9 11 
7 7050 Santhi 33/f 45.2 43 18 15 
8 3467 Theepa 39/f 237 236 19 17 
9 2099 Uma maheshwari 40/f 2.5 1.97 14.8 11.54 
10 9124 Lakshmi 25/f 160 158 29.3 27.6 
11 9125 Vijaya 50/f 7.6 3 24 21.86 
12 1420 Vedavalli 40/f 109.8 107.01 273.4 270.95 
13 3430 Porkodi 31/f 176 174.87 36 35 
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14 4520 Amutha 56/f 53.2 50.99 27.6 24.98 
15 4349 Susmitha 20/f 16 14 28.12 25.09 
16 5290 Kasthuri 60/f 71.52 68.70 34 31 
17 9454 Rajeshwari 49/f 21.6 21 288.20 288 
18 6384 Kamalaveni 48/f 19 18 15.7 14.2 
19 9140 Kavitha 29/f 4 3.8 33.60 33 
20 9635 suriyakumari 59/f 167 165.87 241 2389.68 
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PAIN SCORE FOR GROUP 1 
S.NO OP NO NAME  AGE/ SEX PAIN SCORE 
BT AT 
1 1512 Saratha 51/f 8 5 
2 1395 Thatchayini 58/f 7 4 
3 3260 Uma 32/f 9 9 
4 3259 Raman 54/m 8 7 
5 6446 Selvi 57/f 9 3 
6 7048 Stella 33/f 8 5 
7 7050 Santhi 33/f 9 4 
8 3467 Theepa 39/f 8 2 
9 2099 Uma maheshwari 40/f 9 4 
10 9124 Lakshmi 25/f 7 1 
11 9125 Vijaya 50/f 8 2 
12 1420 Vedavalli 40/f 7 3 
13 3430 Porkodi 31/f 9 4 
14 4520 Amutha 56/f 9 2 
15 4349 Susmitha 20/f 8 3 
16 5290 Kasthuri 60/f 7 2 
17 9454 Rajeshwari 49/f 8 1 
18 6384 Kamalaveni 48/f 9 4 
19 9140 Kavitha 29/f 8 2 
20 9635 suriyakumari 59/f 9 3 
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HAEMATOLOGICAL INVESTIGATION GROUP II 
SI. 
No 
IP. 
NO 
 AG
E/S
EX 
Hb (gm) TC (cu.mm) DC ESR Bl sugar 
NAME p L E ½ hr 1/2hr 1hr 1hr      P.P 
 B
T 
AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 992/438
6 
sandhya 45/F 8 11 8000 7400 64 71 30 24 6 5 40 20 72 42 135 124 
2 793/911
3 
chellama
l 
50/F 7 10.5 6400 8100 60 75 31 22 9 3 60 15 125 32 120 116 
3 906/247
3 
jegatham
bal 
50/F 9.6 10 9400 7300 66 73 28 22 6 5 35 25 70 51 88 97 
4 1314/23
23 
chitra 22/F 10 11.5 10000 8400 52 60 43 32 5 8 6 8 15 18 130 122 
5 1406/48
88 
sittama 45/F 8.9 10.5 8600 7860 65 70 29 25 6 5 64 56 100 89 110 115 
6 1418/52
53 
geeth
a 
37/
F 
8 9.5 67
00 
6500 66 72 23.7 22 2.6 6 65 63 100 96 97 95 
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7 1434/57
20 
krishn
aveni 
60/
F 
9.
5 
10.1 72
00 
6700 65 70 33 25 2 5 56 42 120 105 12
5 
110 
8 1461/63
15 
lalitha 55/
F 
8.
8 
9.9 10
63
0 
8920 70 69.
4 
20 24.
5 
2 1.1 38 23.
5 
96 57 11
0 
98 
9 1544/83
24 
mano
nmani 
59/
F 
1
0.
4 
11.4 11
00
0 
8900 55.
9 
59 34.8 34 2.0 7 18 30 36 52 15
6 
140 
10 1619/14
3 
latha 37/
F 
1
2.
5 
12.8 12,
10
0 
9800 59 63 23 27 18 10 24 20 52 45 13
2 
126 
11 1659/12
64 
radha 46/
F 
1
1 
12 70
00 
8500 70 65 26 30 2 5 30 28 62 56 11
0 
100 
12 1712/15
01 
girija 54/
F 
9.
8 
10 85
00 
8300 58 61 36 30 6 9 32 27 80 60 85 90 
13 577/776 Devi 33/
F 
7.
6 
9 84
00 
8200 60 69 37 27 3 4 32 29 75 62 83 85 
14 639/633
2 
Gokul
arani 
44/
F 
1
0.
4 
11 81
00 
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16 798/161
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00 
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IMMUNOLOGICAL REPORT 
S.NO IP NO NAME AGE/ SEX 
RA FACTOR ANTI CCP 
BT AT BT AT 
1 1045/1003 Sandhya 45/F 86.07 64 101 96 
2 1265/1586 Chellamal 50/F 114 109 99 71 
3 1287/1906 jegathambal 50/F 96 85 79.7 57.38 
4 1314/2323 Chitra 22/F 57 39 100.3 89.24 
5 1406/4888 Sittama 45/F 51 40 72.9 68.4 
6 1418/5253 Geetha 37/F 59 48 99.83 90.2 
7 1434/5720 krishnaveni 60/F 126 116 212 199.37 
8 1461/6315 Lalitha 55/F 71 63 243.67 229 
9 1544/8324 manonmani 59/F 24 18.61 84 71 
10 1619/143 Latha 37/F 40 21 68 51.93 
11 1659/1264 Radha 46/F 90 79 60 42.7 
12 1712/1501 Girija 54/F 112 98.67 184 170.94 
13 577/776 Devi 33/F 20 11.2 36.1 28 
14 639/6332 gokularani 44/F 94.25 76.3 84 73 
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15 676/7451 Uma maheshwari 40/F 
 
264.24 260.81 12 9.64 
16 798/1616 Sankari 44/F 32 28 49.85 45.52 
17 849/3539 Rekha 32/F 33.1 28.67 74 71 
18 856/3629 Uma 36/F 295.1 296 58 57.64 
19 15/486 Alagammal 49/F 53.7 47.3 98.4 87.46 
20 8/175 Valarmathi 49/F 97.6 91.3 124 119 
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LFT, RFT AND URINE ANALYSIS OF GROUP – II SUBJECT 
 
 
 
S.NO 
 
 
 
IP.NO 
 
 
NAME 
 
 
AGE/ 
SEX 
                         LIVER FUNCTION TEST 
BEFORE  TREATMENT AFTER TREATMENT 
Serum Alkaline 
phosphatase 
SGOT SGPT  
 
Serum 
Alkaline 
phosphatase 
SGOT SGPT  
 
1 992/4386 Sandhya 45/F 87 23.2 19.9 76 28.7 24 
2 793/9113 Chellamal 50/F 99 17.7 9.8 87 25.1 14.8 
3 906/2473 jegathambal 50/F 99.4 25.2 27.9 87 21.6 17.8 
4 1314/2323 Chitra 22/F 95 18.6 8.9 86 20.7 14.3 
5 1406/4888 Sittama 45/F 101 31.5 27.1 94 28.7 24.1 
6 1418/5253 Geetha 37/F 83 17.4 12 98 16 15.1 
7 1434/5720 krishnaveni 60/F 106 22 18 98 18.9 16.2 
8 1461/6315 Lalitha 55/F 206 16 22 141 20.8 17.3 
9 1544/8324 manonmani 59/F 105 28 31 97 24 28 
10 1619/143 Latha 37/F 83 13.5 6.5 97 19.3 12.4 
11 1659/1264 Radha 46/F 92 29 24 86 23 20 
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12 1712/1501 Girija 54/F 101 27.8 19.9 90 20.2 27.1 
13 577/776 Devi 33/F 126 30.1 27 113 24 21 
14 639/6332 gokularani 44/F 97 29 22 89 21 19 
15 676/7451 Uma 
maheshwariz 
40/F 
 
154 361.4 206 120 203 174 
16 798/1616 Sankari 44/F 112 17.8 19.3 104 28.1 24.6 
17 849/3539 Rekha 32/F 100 26 19 93 24 16.9 
18 856/3629 Uma 36/F 89 18.3 16.9 92 21.2 24.6 
19 15/486 Alagammal 49/F 95 19.8 21 99 24 26 
20 8/175 Valarmathi 49/F 115 32 26 101 24.8 21 
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RENAL FUNCTION TEST 
 
 
S.NO 
 
 
IP.NO 
 
 
NAME 
AGE/ 
SEX 
RENAL FUNCTION TEST 
BEFORE TREATMANT AFTER TREATMANT 
UREA CREATININE UREA CREATININE 
1 992/4386 Sandhya 45/F 25 0.5 24 0.81 
2 793/9113 Chellamal 50/F 29 0.55 25.1 0.49 
3 906/2473 jegathambal 50/F 25 0.74 22 0.52 
4 1314/2323 Chitra 22/F 15.9 0.52 21 0.64 
5 1406/4888 Sittama 45/F 23 0.9 29 0.76 
6 1418/5253 Geetha 37/F 16 1.1 28 0.73 
7 1434/5720 Krishnaveni 60/F 29 1.1 33 0.87 
8 1461/6315 Lalitha 55/F 15 0.81 21 0.59 
9 1544/8324 Manonmani 59/F 12 0.8 24 0.68 
10 1619/143 Latha 37/F 11.4 0.55 25 0.47 
11 1659/1264 Radha 46/F 16 0.8 22 0.45 
12 1712/1501 Girija 54/F 26 0.99 19.8 0.67 
13 577/776 Devi 33/F 30 1.0 24 0.84 
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14 639/6332 Gokularani 44/F 26 0.85 24 0.61 
15 676/7451 Uma 
maheshwariz 
40/F 
 
9.99 0.53 15 0.48 
16 798/1616 Sankari 44/F 22 0.7 19 0.59 
17 849/3539 Rekha 32/F 30 0.94 21 0.72 
18 856/3629 Uma 36/F 29 0.88 26 0.70 
19 15/486 Alagammal 49/F 34 0.9 27 0.62 
20 8/175 Valarmathi 49/F 28 1.1 24 0.68 
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URINE ALALYSIS OF GROUP II 
 
 
S.NO 
 
 
IP.NO 
NAME AGE/ SEX 
URINE ANALYSIS 
ALBUMIN SUGAR DEPOSIT 
BT AT BT AT BT AT 
1 992/4386 Sandhya 45/F Nil Nil Nil Nil Nil nil 
2 793/9113 Chellamal 50/F Nil Nil Nil Nil Nil nil 
3 906/2473 Jegathambal 50/F Nil Nil Nil Nil Pc 
seen 
Nil  
4 1314/2323 Chitra 22/F Nil Nil Nil Nil Nil Nil  
5 1406/4888 Sittama 45/F  Nil  Nil   Nil   Nil Nil nil 
6 1418/5253 Geetha 37/F Nil Nil Nil Nil Nil Nil  
7 1434/5720 Krishnaveni 60/F Nil  Nil Nil Nil Nil nil 
8 1461/6315 Lalitha 55/F Nil Nil Nil Nil Nil Pc seen 
9 1544/8324 Manonmani 59/F Nil Nil Nil Nil Nil Nil  
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10 1619/143 Latha 37/F Nil Nil Nil Nil Nil Nil  
11 1659/1264 Radha 46/F Nil Nil Nil Nil Nil Nil 
12 1712/1501 Girija 54/F Nil Nil Nil Nil Pc 
seen  
Nil 
13 577/776 Devi 33/F Nil Nil Nil Nil Nil Nil  
14 639/6332 Gokularani 44/F Nil Nil Nil Nil Nil Nil  
15 676/7451 Uma maheshwari 40/F 
 
Nil Nil Nil Nil Nil Pc seen 
16 798/1616 sankari 44/F Nil Nil Nil Nil Nil Nil 
17 849/3539 rekha 32/F Nil Nil Nil Nil Nil  Nil 
18 856/3629 uma 36/F Nil Nil Nil Nil Nil Nil  
19 15/486 Alagammal 49/F Nil Nil Nil Nil Nil Pc seen 
20 8/175 Valarmathi 49/F Nil Nil Nil Nil Nil Nil  
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PAIN SCORE 
S.No Ip.no Name Age / sex Pain score 
Bt At  
1 1045/1003 Sandhya 45/F 9 4 
2 1265/1586 Chellamal 50/F 8 3 
3 1287/1906 jegathambal 50/F 9 4 
4 1314/2323 Chitra 22/F 8 1 
5 1406/4888 Sittama 45/F 8 4 
6 1418/5253 Geetha 37/F 9 2 
7 1434/5720 krishnaveni 60/F 7 1 
8 1461/6315 Lalitha 55/F 8 6 
9 1544/8324 manonmani 59/F 9 2 
10 1619/143 Latha 37/F 7 1 
11 1659/1264 Radha 46/F 8 3 
12 1712/1501 Girija 54/F 9 5 
13 577/776 Devi 33/F 8 3 
14 639/6332 gokularani 44/F 8 2 
15 676/7451 Uma maheshwari 40/F 
 
7 3 
16 798/1616 Sankari 44/F 9 4 
17 849/3539 Rekha 32/F 7 1 
18 856/3629 Uma 36/F 8 8 
19 15/486 Alagammal 49/F 8 2 
20 8/175 Valarmathi 49/F 8 3 
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DISCUSSION 
The main aim of the treatment was to prove the therapeutic effects of the 
drug gandhagarasayanam to reduce pain, swelling, restricted movements of the 
joints in the disease uthiravathasuronitham. It can be co-related with rheumatoid 
arthritis in modern science.  
                  Rheumatoid arthritis is a chronic inflammatory, destructive, and 
deforming symmetrical poly-arthritis associated with symmetrical involvement of 
joints. Uthiravatasuronitham is mainly caused due to imbalance in vatadosham. The 
drugs which pos ses  anti-vatha property as mentioned in siddha literature were 
selected and the trial drug was prepared.the drug was prepared by the standard 
operating procedure as mentioned in the protocol. 
              The clinical study was conducted with a well defined protocol and a proper 
profoma. After screening patients, 40 cases were selected from government siddha 
medical college and hospital attached with Aringar Anna Government Hospital for 
Indian Medicine, Arumbakkam, Chennai-106  during the period 2016-2017. The 
selected cases were treated with the trail medicines both internally and externally. 
AGE: 
The percentage of the age group18-20 was 2.5%, 21-30 was 7.5%, 31-40 was 
32.5%, 41-50 was 30% , 51-60 was 27.5%. 
GENDER: 
Among the 40 patients selected 97.5% were females and 2.5% were males. 
 GUNAM: 
                Among the 40 cases, 38 cases were found to possess rasatha gunam and 2 
cases were found to possess thamo gunam. 
BODY CONSTITUTION: 
In the study 3 cases belongs to vadha thegi  and 37 cases belongs to thontha 
thegi. 
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PARUVAKALAM: 
 Among the 40 cases, 27.5% of cases were admitted to the trail in 
kaarkaalam,22.5% of cases  in koothirkalam and 10% cases in munpanikalam,12.5% 
in pinpani kalam 7.5% cases in ilavenilkalam,20% in mudhuvenilkaalam. 
NILAM: 
Among 40 cases, 5% cases were under marutha nilam, and the remaining 95%cases 
were under neithal nilam. 
DIET: 
Among 40 cases,87.5% were nonvegetarian and 12.5% were vegetarian diet. 
OCCUPATIONAL DISTRIBUTION: 
 Among 40 cases, 62.5% were housewives, 12.5% were farmers,10% were 
housemaids and clericals , and  2.5%were drivers and teachers. 
SOCIO-ECONOMIC STATUS: 
The incidence of the disease was found in 62.5% in middle class ,27.5% in poor and 
10% in upper middle class . 
DURATION OF ILLNESS: 
         Among the 40 cases, the duration of the illness at the time of study 27.5% 
were 1yr-2yrs, 25% were 2-5 yrs, 20% were 6months- 1yr, 17.5% were 3months- 6 
months, 7.5% were 5-10 yrs, 2.5% were more than 10 yrs. 
ONSET OF SYMPTOMS: 
All the cases were of gradual onset only. 
VATHAM: 
               Samaanan,viyaanan  were affected in 100% of cases, dhevathathan was 
affected in 77.5% cases, praanan, udhaanan were affected in 60% of cases, naagan, 
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koorman, kirukaran, were affected in 30% of cases. Abaanan was affected in 10% of 
cases. 
PITHAM: 
         Among  the  40  cases,  saathagam  was  affected  in  100%cases.  Analam  was  
affected in 37.5% of cases, ranjagam was affected in 32.5% cases, alosagam was 
affected in 30% cases, prasagam was affected in 2.5% cases. 
KABAM: 
            Among 40 cases, santhigam was affected in 100% cases, avalambagam was 
affected in 60% cases, kilethagam was affected in 37.5% cases, tharpagam was 
affected in 35% cases, pothagam was affected in 5% cases. 
GNANENTHRIYAM: 
Among the 40 cases all mei was affected in 100%cases, vai was affected in 5% 
cases.  
KANMENTHIRIYAM: 
         Among the 40 cases, kai kaal are affected in all 100% cases due to pain, 
swelling, restriction of movements,etc. eruvaai was affected in 10% of cases due to 
constipation, vaai was affected in 5% of cases due to stomatitis. 
UDAL THATHUKKAL: 
          Among 40 cases, saaram, seneer, oon, kozhuppu, enbu, moolai were affected 
in all 40 cases. 
ENVAGAI THERVUGAL:  
       In all the cases, examination of naadi, naadi revealed thontham of vatham. 
Sparisam was affected in 67.5% cases due to warmth felt in the affected joints. 
Vizhi was affected in 45% cases , naa was affected in 35% of cases, and mala was 
affected in 10% cases, niram was affected in 2.5%    
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NAADI: 
           Among 40 cases, vatha pitta nadi was found in 75% cases, pithavathanadi 
was found in 25% cases. 
NEIKKURI: 
Among 40 cases, 77.5% cases showed vathaneer,17.5% cases showed kabhaneer, 
and 5% cases showed pittaneer. 
CLINICAL FEATURES: 
                  Pain, swelling of joints, morning stiffness, tenderness, restricted 
movements and warmth were found in all 40 cases before treatment. 
After treatment there was a considerable reduction in all symptoms particularly in 
pain, morning stiffness, swelling of joints, tenderness, restricted movements and 
warmth. 
DEFORMITIES: 
               Out of 40 cases, 25% cases had spindle shaped finger, 12.5% cases had 
ulnar deviation of hand, 7.5% cases had hallus valgus and 7.5% cases had swan 
neck deformity. 
INVOLVEMENT OF JOINTS: 
            Among the 40 cases, 100% had knee joint, 87.5% cases had proximal 
interphalangeal joint, ankle joint and metacarpo phalangeal joint, 75% had wrist 
joint, 65% had cervical spine, 32% had elbows, 25% had hip joints, shoulder joints, 
and metatarso phalangeal joint. 
ANALYSIS AFTER TREATMENT: 
Among 40 patients 80% of cases shows good results , 12.5% of cases shows 
moderate results &7.5 % of cases shows mild results. 
 
 
                
 
 
 
 
 
 
 
 
 
 
                                          SUMMARY 
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SUMMARY 
               Uthiravatha suronitham is one among the 80 types of vatha diseases 
classified by Yugimuni. In modern, uthira vatha  suronitham is being co-related with 
rheumatoid arthritis. 
               The main aim of this study was to prove the efficacy of gandhaga 
rasayanam and navanathasittha thailam in uthiravatha suronitham.  
               Before  Clinical  trail   pre  clinical  analysis  such  as  physiochemical  
analysis,toxicity studies,antimicroibial studies and pharmacological studies were 
carried out.  
               Clinically 40 cases which was diagnosed with RA were selected and 
treated with the trail drugs gandhaga rasayanam [internal], and navanathasittha 
thailam [external]. 
             Before starting the treatment, the patients were given clear and complete 
information regarding the treatment protocol and dietary regimens.  
             Initially the patient was advised to undergo purgation before starting the 
treatment. 
             Later the trail drugs gandhaga rasayanam [internal] and navanathasittha 
thailam  [  external]  was  administered  to  the  patients  for  a  period  of  48days  [  1  
mandalam].  
             During the period of treatment the patients were under  dietary regimen (dos 
and donts for vatha disease) 
             Daily changes of the patients were monitored and recorded. Incase of 
adverse drug reactions, the case was being withdrawn from the treatment.  
             From this study, it is proved that the gandhaka rasayanam and 
navanathasittha tailam has a good therapeutic effect over uthiravatha suronitham. 
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            The results of the outcome of the trail medicines by grading methods were as 
follows: 
¾ Good improvement - 80% 
¾ Moderate improvement -12.5% 
¾ Mild improvement -7.5% 
¾ No improvement -    --- 
             
     
 
 
 
 
         
                           
 
 
 
 
 
 
 
 
 
 
                
                                    
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
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CONCLUSION 
Uthiravathasuronitham is being co-related to rheumatoid arthritis in modern 
medicine. Rheumatoid arthritis is a chronic inflammatory, destructive and 
deforming , symmetrical poly arthritis associated with symmetrical involvement of 
joints.  
Uthiravathasuronitham mainly occurs due to de- arrangement of vatha and 
pitta dosham .  
The Toxicological studies  reveals that the trial drug doesn’t show any 
toxicity in rat models. 
The pre-clinical studies shows that the trail drug has got significant Anti-
inflammatory against carageenan induced paw edema method and Analgesic action 
against acetic acid induced writhing test. 
The clinical study proves remarkable decrease in the symptoms of the 
disease. 
The biostatistical analysis declares that the effect of the trial drug is 
remarkable.  
The study proves the therapeutic effect of the drug gandhaga rasayanam (int) 
and navanathasittha tailam (ext) over morning stiffness, pain,  swelling, restricted 
movements, etc. were significant and no adverse effects were reported during the 
course of treatment. 
After  undergoing  the  treatment,  the  patients  were  able  to  do  their  daily  
routine by themselves without any others help.  
The main aim of the treatment was to normalize the de-arranged dosham and 
to retrieve from the symptoms and overall quality of life. 
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             Annexures  
                                             Toxicological study 
Acute toxicity activity: 
               Acute toxicity study was carried out as per OECD guideline (Organization 
for Economic Co - operation and Development, Guideline-423 
Animal : Healthy swiss albino female rat weighing 220–240 gm 
Studied carried out at three female rat under fasting condition, signs of toxicity was 
observed for every one hour for first 24 hours and every day for about 14 days from 
the beginning of the study. 
INTRODUCTION:  
The acute toxic class method is a stepwise procedure with the use of 3 animals of a 
single sex per step. Depending on the mortality and/or the moribund status of the 
animals, on average 2-4 steps may be necessary to allow judgment on the acute 
toxicity of the test substance. Morbid animals or animals obviously in pain or 
showing signs of severe and enduring distress shall be humanely killed, and are 
considered in the interpretation of the test   results  in  the  same  way  as  animals  
that  died  on  test.  The method allows for the determination of an LD50 value only 
when at least two doses result in mortality higher than 0% and lower than 100%. 
 
PRINCIPLE:  
  It  is  the principle of the test  that  based on a stepwise procedure with the use of a 
minimum  number  of  animals  per  step,  sufficient  information  is  obtained  on  
the  acute toxicity  of  the  test  substance  to  enable  its  classification.  The 
substance is administered orally to a group of experimental animals at one of the 
defined doses.  The substance is tested using a stepwise procedure, each step using 
three animals of a single sex. Absence or presence of compound-related mortality of 
the animals dosed at one step will determine the next step, i.e.; í no further testing is 
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needed  í dosing  of  three  additional  animals  with  the  same dose  í dosing  of  three  
additional animals at the next higher or the next lower dose level. The method will 
enable a judgment with respect to classifying the test substance to one of a series of 
toxicity classes.   
METHODOLOGY: 
Selection of animal species:  
  The preferred rodent species is rat, although other rodent species may be used.  
Healthy  young  adult  animals  of  commonly  used  laboratory  strain Swiss albino 
is used .  Females should be nulliparous and non-pregnant.  Each animal at the 
commencement of its dosing should be between 8 and 12 weeks old and its weight 
should fall in an interval within±20 % of the mean weight of the animals.   
 
 
Housing and feeding conditions:   
  The  temperature  in  the  experimental   animal  room  should  be  22ºC  (+3ºC).  
Although  the   relative   humidity   should   be   at   least   30%  and   preferably   not   
exceed  70% other than during room cleaning the aim should be 50-60%. Lighting 
should be artificial, the sequence being 12 hrs  light, 12 hrs dark. For feeding, 
conventional laboratory diets may be used with an unlimited supply of drinking 
water. Animals may be grouped and tagged by dose, but the number of animals per 
cage must not interfere with clear observations of each animal.   
Preparation of animals:   
  The animals are randomly selected, marked to permit individual identification, and 
kept in their cages for at least 7 days prior to dosing to allow for acclimatization to 
the laboratory conditions.  
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Observation done: 
Group Day 
Body weight Normal 
Assessments of posture Normal 
Signs of Convulsion 
Limb paralysis 
Absence of sign (-) 
Body tone Normal 
Lacrimation Absence 
Salivation Absence 
Change in skin color No significant colour change 
Piloerection Normal 
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Defecation Normal 
Sensitivity response Normal 
Locomotion Normal 
Muscle grip ness Normal 
Rearing Mild 
Urination Normal 
 
 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
2000 + - - - - + - - - - - + - + - - - - - - 
 
1. Alertness 2.Aggressiveness 3. Pile erection 4. Grooming   5.Gripping   6. Touch 
Response 7. Decreased Motor Activity   8.Tremors 9 Convulsions 10. Muscle 
Spasm 11. Catatonia 12.Musclerelaxant 13.Hypnosis 14.Analgesia15.Lacrimation 
16. Exophthalmos 17. Diarrhea  18. Writhing   19 Respiration   20.  Mortality. 
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Sub-chronic toxicity test  
 
Repeat-dose  oral  toxicity  study  was  carried out  according  to  OECD  guideline  
407.The animals were divided into three groups of 8  animals  each  (4  males  and  
4  females).  
Group I   received  10  ml/kg  body  weight  of distilled water and served as control. 
Groups  
II   and group III received   extract  doses  of  100mg/kg and 200 mg/kg  body  wt,  
respectively.  The drug was  administered  daily  for  28  days the  same  time  daily  
and  observed  at  least  
twice daily  for  morbidity  and  mortality.  
On  the  29th  day,  after  an  overnight  fast,  the rats were anaesthetized with ether 
and  blood  sample   for   hematological   and   biochemical  analysis   were   collected   
into  tubes  with  and without  EDTA,  respectively. 
Histopathology studies were carried out on liver, kidney  and spleen and recorded 
HAEMOTOLOGY 
CBC 
WBC     :   7,500 cells/cumm 
Differential Count 
NEUTROPHILLS  : 14 % 
LYMPHOCYTES  : 85 % 
EOSINOPHILS  : 01 % 
MONOCYTES  : 00 % 
RBC    : 5.67millions/cumm 
HB     : 12.5gms%  
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PCV     : 31.2 % 
MCV     : 55.0fL 
MCH     : 22.0pg  
MCHC   : 40.1 Grams/dl  
PLATELET   : 1.83 Lakhs/cumm 
BIOCHEMISTRY 
Blood sugar   :  71 mg/dl 
BUN     :  56.5 mg/dl 
Creatinine   :  1.5 mg/dl 
SGOT   :  150  U/L 
SGPT    :  87  U/L 
ALP     :  370    U/L 
T.Protein   :  8.3  grams/dl 
Albumin   :  4.0  grams/dl 
LIPID PROFILE 
T. Cholesterol  :  108 mg/dl 
Triglycerides  :  70  mg/dl 
HDL    :  26 mg/dl 
LDL     :  68  mg/dl 
VLDL   :  14.0  mg/dl 
Ratio 1(T.CHO/HDL)     :  4.1 
Ratio 2(LDL/HDL) :  2.6 
  
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACOLOGICAL 
ACTIVITIES 
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                                                           ANNEXURE -3 
                                           PHARMACOLOGICAL ANALYSIS 
                          ANALGESIC ACTION OF GANDHAGA RASAYANAM 
                   
Acetic acid Induced Writhing Test : olufunnmilayo et al 
AIM: 
The  analgesic  activity  of  the  Gandhagarasayanam  was  evaluated  using  acetic  acid  
induced writhing method in mice.  
MATERIALS AND METHODS: 
PROCEDURE: 
Here acetic acid is administered intra-peritoneally to the experimental animals to 
create pain sensation. Reference drug is aspirin. Animals are randomly allotted as 5 
groups , 5 animals in each group. The control group received 10ml/kg distilled water 
orally. The reference group received DICLOFENAC SODIUM 25mg/kg (dissolved 
in distilled water) p.o.  Groups 3, 4 and 5 were orally pretreated with sample 100mg 
and 200mg/kg respectively.  All the drugs were administered 30 min before i.p. 
injection of 0.6 % v/v 1ml/kg glacial acetic acid.  The number or writhing (extension 
of hind limb as a result of contraction of abdominal muscle).  Immediately after the 
injection of acetic acid was counted for 30mins. The reduction in writhing is 
indication of analgesic property. 
Result:   
Treatment Dose No of writhing (mean ±S.E.M) Inhibition (%) 
Control (Saline) 10ml/kg 28.33± 1.16 - 
Gandhagarasayanam100mg 19.00±0.51 32.93 
Gandhagarasayanam200mg 10.33±0.66 63.53 
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 INFERENCE: 
             From the above table it is clear that the drug gandhaga rasayanam has 
significant anti analgestic activity. 
ANTI-INFLAMMATORY ACTIVITY OF GANDHAGA 
RASAYANAM[WINTER ET AL ] : 
AIM: 
The anti-inflammatory activity of Gandhagarasayanam was determined by 
carageenan induced paw edema method. 
MATERIALS AND METHODS: 
PROCEDURE: 
  Rats  are  randomly  alloted  in  4  groups,  6  animals  in  each  group.  Paw edema was  
induced by 0.1ml of 1% carageenan in physiological saline into the sub planar tissue 
of left hind paw of each rat.  Samples (100mg, 200mg/kg) were administered orally 
30 mins prior to carageenan. 
Group-I:  animals (carrageenan control) received vehicle 30 min prior to 
administration of carrageenan injection.  
Group-II: animals the standard reference group was given p.o. aqueous solution of 
Indomethacin (5 mg/kg), 30 min prior administration carrageenan injection.   
Group-III: animals received 100mg/kg Gandhagarasayanam 30 min prior to 
administration of carrageenan injection. 
Group-IV: animals received 200mg/kg of Gandhagarasayanam 30 min prior to 
administration of carrageenan injection. 
The paw volume was measured using plethysmograph immediately after 1hr of 
injection, again at 2, 3, and 4th hour eventually after treatment. The mean volume 
was compared with control group 
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Result: 
 The details of the experimental results are shown in the table which indicates the 
effect of GANDHAGA RASAYANAM. 
 
Group Dose 
mg/kg 
Mean Paw volume in ml 
1hr 2hr 3hr 4hr 
Control Vehicle 1.333±0.01
60 
1.333±
 0.0
176 
1.440±0.008
1 
1.530±0.01
29 
Indomethacin 5mg/kg 1.296±
 0.0
116 
1.280±0.00
89 
1.272±0.010
2 
1.012±0.02
41 
Gandhagarasaya
nam 
100mg/
kg 
1.452±0.01
02 
1.372±0.00
48 
1.320±0.014
1 
1.284±0.01
32 
Gandhagarasaya
nam 
200mg/
kg 
1.502±0.01
02 
1.446±0.00
97 
1.356±0.013
270 
1.300±0.02
00 
 
 Effect of Gandhaga Rasayanam in Carageenin induced rat paw edema 
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Inference: 
       The test  drug “  GANDHAGA RASAYANAM” has got significant acute anti-  
inflammatory effect when compared with the standard drug. 
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Histopathology of kidney 
 
 
10 x magnification      40 x magnification 
GandhagaRasayanam 100 mg 
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10 x magnification     40 x magnification 
GandhagaRasayanam 200 mg 
 
Report  
Section studied shows congestion of peri tubular vessel. The glomeruli and tubules 
show normal histology 
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Histopathology of liver 
 
 
10 x magnification      40 x magnification 
GandhagaRasayanam 100 mg 
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10 x magnification      40 x magnification 
GandhagaRasayanam 200 mg 
Report 
Section studied shows normal lobular pattern. 
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Histopathology of spleen 
E
  
10 x magnification    `    40 x magnification 
GandhagaRasayanam 100 mg 
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10 x magnification       40 x magnification 
GandhagaRasayanam 200 mg 
Report  
Section studied shows plenty of intra parenchymal hemosiderin laden 
macrophages. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
BIOSTATISTICAL        
ANALYSIS  
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                                          BIOSTATISTICAL ANALYSIS 
 
  
CLINICAL PROGNOSIS 
IMPROVE MENT OF GROUP I SUBJECTS:  
The most popular non parametric statistical tool, namely, McNemar Test 
analysis has been employed to analyses the effectiveness with the help of a 
hypothesis. 
IMPROVE MENT OF GROUP I SUBJECTS:  
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. Morning Stiffness 20(100) 3(15)** 
2. Pain And Swelling of 
Joints 
20(100) 4(20)** 
3. Arthritis of 3or more 
JOINTS 
12(60) 4(20)** 
4. Symmetrical Involvement 10(50) 3(15)** 
5. Restriction of Movements 20(100) 2(10)** 
6. Low Grade Fever 15(75) 1(5) ** 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features. So there is significant 
reducing of clinical features among the patients for the treatment of rheumatoid 
rthritis.. Hence it is concluded that the treatment was effective and significant. 
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IMPROVEMENT OF GROUP II SUBJECTS:  
  
The most popular non parametric statistical tool, namely, McNemar Test 
analysis has been employed to analyses the effectiveness with the help of a 
hypothesis. 
IMPROVE MENT OF GROUP II SUBJECTS:  
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. Morning Stiffness 20(100) 4(20)** 
2. Pain And Swelling of 
Joints 
20(100) 4(20)** 
3. Arthritis of 3or more 
JOINTS 
13(65) 3(15)** 
4. Symmetrical Involvement 10(50) 2(10)** 
5. Restriction of Movements 20(100) 3(15)** 
6. Low Grade Fever 12(60) 1(5) ** 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features. So there is significant 
reducing of clinical features among the patients for the treatment of rheumatoid 
arthritis. Hence it is concluded that the treatment was effective and significant. 
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Group I Subjects : Liver Function Test 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
2 SGPT 16.43±4.46 18.08±4.81 <0.05 
3 SGOT 19.61±4.39 20.61±4.86 0.184 
4 Alkaline Phosphatase 87.72±19.86 89.28±11.17 0.547 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
Group II Subjects :Liver Function Test 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
2 SGPT 20.21±6.75 20.06±4.67 0.906 
3 SGOT 40.21±7.58 31.85±4.41 0.309 
4 Alkaline Phosphatase 107.27±28.27 97.40±14.20 <0.05 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
 
GROUP I SUBJECTS :RFT 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 22.62±6.58 21.79±5.32 0.483 
2 Creatinine 0.79±0.14 0.65±0.13 <0.001  
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant.  
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GROUP II SUBJECTS: RFT 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 22.61±7.30 23.69±3.93 0.489  
2 Creatinine 0.81±0.20 0.64±0.12 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
GROUP I SUBJECTS: BLOOD INVESTIGATION 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 11.11±1.59 11.80±1.02 <0.05  
2 ESR1hr 48.00±16.38 38.55±12.21 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
GROUP II SUBJECTS: BLOOD INVESTIGATION 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 9.72±1.47 10.93±1.00 <0.001  
2 ESR1 hr 68.55±30.00 52.95±22.89 <0.05 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
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OP Cases 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 RA Factor 77.85±69.04 76.17±69.35 <0.001  
2 Anti CCP 69.82±94.16 67.85±94.33 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
IP Cases 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 RA Factor 90.80±72.00 81.04±74.41 <0.001  
2 Anti CCP 97.03±56.99 86.42±55.43 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
PAIN SCALE BEFORE AND AFTER TREATMENT 
OP Cases 
S.No. BT 
PAIN  
Scale 
AT 
PAIN  
Scale 
1 8 5 
2 7 4 
3 9 9 
4 8 7 
5 9 3 
6 8 5 
 181 
 
7 9 4 
8 8 2 
9 9 4 
10 7 1 
11 8 2 
12 7 3 
13 9 4 
14 9 2 
15 8 3 
16 7 2 
17 8 1 
18 9 4 
19 8 2 
20 9 3 
Software: spss17 version 
Variables: PAIN Scale – before treatment, after treatment 
Number of cases: 20 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.315 
Before and after treatment mean difference: 4.70 ± 1.86. 
P Value (2 tailed): p<0.001. 
Inference:  
Since the P value is highly significant (<0.001). So there is significant 
reducing  of  PAIN  Scale  among  the  patients  for  the  treatment  of  rheumatoid  
arthritis.. Hence it is concluded that the treatment was effective and significant. 
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IP Cases 
S.No. BT 
PAIN  
Scale 
AT 
PAIN  
Scale 
1 9 4 
2 8 3 
3 9 4 
4 8 1 
5 8 4 
6 9 2 
7 7 1 
8 8 6 
9 9 2 
10 7 1 
11 8 3 
12 9 5 
13 8 3 
14 8 2 
15 7 3 
16 9 4 
17 7 1 
18 8 8 
19 8 2 
20 8 3 
 
Software: spss17 version 
Variables: PAIN Scale – before treatment, after treatment 
Number of cases: 20 
Test: Paired t test 
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Confidence Interval: 95% 
Correlation coefficient (r): 0.358 
Before and after treatment mean difference: 5.00 ± 1.68. 
P Value (2 tailed): p<0.001. 
Inference:  
Since the P value is highly significant (<0.001). So there is significant 
reducing of PAIN Scale among the patients for the treatment of rheumatoid arhritis. 
Hence it is concluded that the treatment was effective and significant.  
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CASE SHEET PROFORMA 
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GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A  CLINICAL TRIAL OF “UTHIRAVATHASURONITHAM’’ (RHEUMATOID 
ARTHRITIS) WITH THE SIDDHA DRUG “GANDHAGA RASAYANAM”(INT) 
& “NAVANATHASITTHA THAILAM”(EXT). 
FORM l - SCREENING AND SELECTION PROFORMA 
1.OP NO:  ................................................................. 
2. NAME:  ………………………………………….  
3. AGE:      ………       4.GENDER: …………....... 
5. OCCUPATION: ………………………………..      6.INCOME:   
………………… 
7. ADDRESS:    ……………………………………    
…………………………………… 
…………………………………… 
8. CONTACT NO:    ……………………………………              
 INCLUSION CRITERIA: 
• Age :  18-40 Yrs                 Yes / No 
• Sex: Both male and female.                                                 Yes/No                      
                                                                                                                                                                                                         
• Patients having Arthritis of 3 or more joints.                         Yes/No 
• Patient having RA factor positive.                                         Yes/No                                                           
• Patients who are willing to undergo Laboratory investigation.  
                                                                             Yes / No 
• Patients  who  are  willing  to  sign  the  informed  consent  stating  that  He/She  
will conscientiously stick to the treatment during 20days but can opt out of the trial 
of his/her own conscious discretion.                                       Yes / No 
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EXCLUSION CRITERIA 
Rheumatic fever 
History of sulphur allergy 
Psoriatic arthropathica 
Gouty arthritis  
ASO positive 
Sero negative polyarthritis 
Progressive systemic sclerosis(PSS) 
Any other serious illness 
 
ADMITTED TO TRIAL: 
                          YES                        NO                 
 
 
 
      If yes,             OPD/IPD                    
 
 
 
Date:        
Station: 
   Signature of the Guide                                     Signature of the Investigator       
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                                    GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
 POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A  CLINICAL TRIAL OF “UTHIRAVATHASURONITHAM’’ (RHEUMATOID 
ARTHRITIS) WITH THE SIDDHA DRUG “GANDHAGA RASAYANAM”(INT) 
& “NAVANATHASITTHA THAILAM”(EXT) 
FORM lI -HISTORY TAKING PROFORMA 
1.  SERIAL  NO  OF  THE  CASE:  …….    2.OP/IP  NO:  
....................................................   
3. NAME: ………………………………………… 4. AGE: …….. 5. GENDER: 
…….. 
5. OCCUPATION: ………………………………      6. INCOME: 
7. COMPLAINTS & DURATION:   
8. PERSONAL HISTORY: 
9. HISTORY OF PREVIOUS ILLNESS 
10. BIRTH HISTORY 
11. DIETARY HABIT:     
             1. Vegetarian              
             2. Non-vegetarian 
12. FAMILY HISTORY: 
               Whether this problem runs in family? 
                                         1. Yes                               2.No         
               If yes, mention the relationship of affected person(s) --------------------- 
               History of previous investigations if any ------------------------------ 
Date:          
Station:                                              
Signature of the Guide                                             Signature of the Investigator   
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                                   GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A CLINICAL TRIAL OF “UTHIRAVATHASURONITHAM”(RHEUMATOID 
ARTHRITIS) WITH THE SIDDHA DRUG “GANDHAGA 
RASAYANAM”(INT)&”NAVANATHASITTHA THAILAM”(EXT). 
FORM III: ASSESSMENT PROFORMA 
1. SERIAL NO: …………………   
2. OP / IP NO: ......................................   
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................            
GENERAL EXAMINATION: 
Height (cms)                 : ………………………….                   
Weight (kg)    : ………………………….                   
Temperature (°F)     : ………………………….                   
Pulse rate (/min)   : ………………………….                   
Heart rate (/min)   : ………………………….                   
Respiratory rate (/min)  : ………………………….                   
Blood pressure (mm/Hg)       : ………………………….           
 Present           Absent 
Pallor  
Jaundice 
Cyanosis 
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Lymphadenopathy 
Pedal edema 
Clubbing  
Jugular vein pulsation 
                                                                                                                                                                                                                                                          
SYSTEMIC EXAMINATION 
Cardiovascular System  : ………………………….                   
 
Respiratory system   : ………………………….                   
 
Gastro-intestinal system  : ………………………….                   
 
Central Nervous System  : ………………………….                   
 
Urogenital system   : ………………………….                   
 
Endocrine System   : ………………………….                   
SIDDHA SYSTEM OF EXAMINATIONS: 
1. THEGI:  [BODY CONSTITUTION]  
1. Vatha udal 
2. Pitha udal 
3. Kaba udal 
4. Thontha udal        
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2. NILAM:  [LAND WHERE PATIENT LIVED MOST] 
   1. Kurinji    (Hilly terrain)                                   
   2. Mullai    (Forest range)                       
    3. Marutham     (Plains)                            
4. Neithal     (Coastal belt)                    
     5. Paalai  (Arid regions) 
3. KAALAM: 
1. Kaar kaalam                               4.Pinpani kaalam      
2. Koothir kaalam                           5. Ilavenil kaalam 
3. Munpani kaalam                           6.Muthuvenil kaalam 
4. GUNAM: 
           1.Sathuvam                2.Raasatham             3.Thaamatham 
5. IMPORIGAL (SENSORY ORGANS): 
                                                                        Normal/Affected 
Mei     - ----------------------------------------------- 
Vaai       ----------------------------------------------- 
Kann  -------------------------------------------------------- 
Mukku ------------------------------------------------------- 
Sevi ------------------------------------------------ 
6. KANMENDHIRIYAM (MOTOR ORGANS): 
Kai    ----------------------------------                
Kal    ------------------------------------ 
Vaai  ------------------------------------ 
Eruvai  ---------------------------------- 
Karuvaai  --------------------------------- 
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7. KOSANGAL (SHEATH): 
Annamaya kosam ------------------------ 
Pranamaya kosam -------------------------- 
Manomaya kosam ------------------------------- 
Vignana maya kosam ----------------------------- 
Anandamaya kosam ------------------------------- 
8. UYIR THAATHUKKAL: [THREE HUMORS] (VALI,  AZHAL, IYAM) 
A) VALI 
 Pranan –-------------------- 
Abanan -------------------- 
Samanan --------------------- 
Uthanan ------------------------ 
Vyanan ------------------------- 
Naagan --------------------------- 
Koorman ----------------------------- 
Kirukaran ---------------------------- 
Devathathan ---------------------------- 
Dhananjayan ---------------------------- 
B) AZHAL 
Analakam -------------------- 
Ranjakam --------------------- 
Sathakam ----------------------- 
Prasakam ------------------------ 
Alosakam -------------------------- 
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C) IYAM 
Avalambagam ------------------------ 
Kilethagam --------------------------- 
Pothagam ------------------------------ 
Tharpagam ---------------------------- 
Santhigam ------------------------------ 
9. SEVEN UDAL THATHUKKAL: (SEVEN SOMATIC COMPONENTS)  
Saram ----------------------- 
Senneer ------------------- 
Oon -------------------------- 
Koluppu ----------------------- 
Enbu --------------------------- 
Moolai --------------------------- 
Sronitham ------------------------- 
10. ENVAGAI THERVU: 
I. NAADI: [PULSE PERCEPTION]         
II. SPARISAM: [PALPATION] 
III. NAA: [TONGUE] 
 IV.NIRAM: [COMPLEXION]   
    1. Vadham         
     2. Pitham 
      3. Kabam  
V.MOZHI: [VOICE] 
            1. High Pitched 
                        2. Low Pitched                         
                        3. Medium Pitched 
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VI.VIZHI: [EYES] 
VII. MALAM: [BOWEL HABITS / STOOLS] 
Niram 
Irugal 
Ilagal 
Others 
 VIII. MOOTHIRAM [URINE EXAMINATION]   
NEERKKURI: 
Niram 
Manam 
Edai 
Nurai 
Enjal 
NEIKKURI 
Date:      
Station: 
 
 
Signature of the Guide                                         Signature of the Investigator   
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  GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A CLINICAL TRIAL OF “UTHIRAVATHASURONITHAM”(RHEUMATOID 
ARTHRITIS) WITH THE SIDDHA DRUG “GANDHAGA 
RASAYANAM”(INT)&”NAVANATHASITTHA THAILAM”(EXT). 
FORM IV : LABORATORY INVESTIGATIONS PROFORMA 
1. SERIAL NO OF THE CASE: …………………   
2. OP / IP NO: ......................................   
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................   
A) BLOOD INVESTIGATIONS:                        
BLOOD INVESTIGATIONS BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Hb ( gm/dL)   
ESR (mm) ½ hr.   
  1 hr.   
T.WBC (Cells / Cu.mm)   
Differential 
Count (%) 
Polymorphs   
  Lymphocytes   
  Monocytes   
  Eosinophils   
  Basophils   
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 INVESTIGATIONS BEFORE 
TREATMENT 
AFTER 
TREATMEN
T 
1 LFT   
 
2 
KFT   
 
B) URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT AFTER TREATMENT 
Albumin   
          Sugar   
Deposits   
 
 
Date:          
Station: 
 
Signature of the Guide                                               Signature of the Investigator   
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    GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
A CLINICAL TRIAL OF “UTHIRAVADHASURONITHAM’’ 
(RHEUMATOID ARTHRITIS) WITH THE SIDDHA DRUG “GANDHAGA 
RASAYANAM”(INT) & “NAVANATHASITTHA THAILAM”(EXT). 
                                       FORM V:  CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have 
had the opportunity to ask questions about it and any questions I have asked have 
been answered to my satisfaction. 
            I   consent voluntarily to participate in this study and understand that I 
have the   right to withdraw from the study at any time without in any way it 
affecting my chid further medical care”. 
"I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the 
potential participant, and the individual has had the opportunity to ask questions. 
I confirm that the individual has given consent freely.”                                         
Date: 
 Signature of a witness                               Left thumb Impression of the Participant     
(Selected by the participant bearing no connection with the survey team)       
Date:    
Station:                                                                                  
Signature of participant:                                             
Signature of the Guide                                Signature of the Investigato 
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GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI-106 
POST- GRADUATE DEPARTMENT OF “SIRAPPU MARUTHUVAM” 
A   CLINICAL  TRIAL  OF “UTHIRAVATHASURONITHAM’’ 
(RHEUMATOID ARTHRITIS) WITH THE SIDDHA DRUG “GANDHAGA 
RASAYANAM” (INT) & “NAVANATHASITTHA THAILAM” (EXT) 
  FORM VI - WITHDRAWAL FORM 
SI NO:                 
OP / IP NO:                                               
NAME: 
AGE / GENDER:                
DATE OF TRIAL COMMENCEMENT: 
DATE OF WITHDRAWAL FROM TRIAL: 
REASONS FOR WITHDRAWAL: 
• Long absence at reporting :                                    Yes/ No 
• Irregular treatment:                                                Yes/ No 
• Shift of locality :                                                    Yes/No 
• Increase in severity of symptoms:                         Yes/No 
• Development of severe adverse drug reactions:    Yes/No 
Date:          
Station: 
 Signature of the Guide                                     Signature of the Investigator   
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                                 GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A   CLINICAL  TRIAL  OF “UTHIRAVATHASURONITHAM’’ 
(RHEUMATOID ARTHRITIS) WITH THE SIDDHA DRUG “GANDHAGA 
RASAYANAM” (INT) & “NAVANATHASITTHA THAILAM” (EXT). 
FORM VII – PATIENT INFORMATION SHEET 
Name of Co- Investigator: M.SHRISARANYA.         Name of the college:  
                                                                                    Govt.Siddha Medical  College 
                                                                                     Arumbakkam 
                                                                               Chennai-106. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
       I, M.Shrisaranya studying M.D (Siddha) at Govt.Siddha Medical College, 
Chennai, is doing a clinical trial on “Uthiravathasuronitham” (Rheumatoid 
Arthritis). It is becoming a most common disease, occurring throughout the world. 
In this regard, I am in need to ask you few questions. I will maintain confidentiality 
of your comments and data obtained. There will be no risk of disclosing your 
identity and no physical, psychological or professional risk is involved by taking 
part  in  this  study.  Taking  part  in  this  study  is  voluntary.  No compensation  will  be  
paid to you for taking part in this study. 
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking  part  in  the  study  may  be  of  benefit  to  the  community,  as  it  may  help  us  to  
understand the problem of defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the 
study primarily by signing the consent form and then you will be given the internal 
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medicine Gandhaga rasayanam,5 gm bid with hot water for 40 days & 
Navanathasiddha thailam for external use. 
  The  information  I  am collecting  in  this  study  will  remain  between you and  
the Co- investigator (myself). I will ask you few questions through a questionnaire. I 
will not write your name on this form. I will use a code instead. 
The questionnaire will take approximately 20 minutes of your time. 
If you wish to find out more about this study before taking part, you can ask 
me  all  the  questions  you  want  or  contact  M.Shrisaranya,  PG  Scholar  cum  Co-
investigator of this study, attached to Govt. Siddha Medical College, Chennai-106. 
You can also contact the Member-secretary of Ethics committee, Govt.Siddha 
Medical College, Chennai. 
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                                   GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106  
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
  A  CLINICAL TRIAL OF “UTHIRAVATHASURONITHAM’’ 
(RHEUMATOID ARTHRITIS) WITH THE SIDDHA DRUG “GANDHAGA 
RASAYANAM” (INT) & “NAVANATHASITTHA THAILAM” (EXT) 
FORM X: ADVERSE REACTION REPORTING FORM 
 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                    AGE:                                          GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF OCCURRENCE OF THE ADVERSE REACTION:  TIME: 
DESCRIPTION OF ADVERSE REACTION: 
 
MANAGEMENT: 
 
Date:                                                                              
Station: 
 
Signature of the Guide                                    Signature of the Investigator   
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